The present invention relates to a foamable composition of matter comprising iodine. The invention further relates to compositions that, when provided in a suitable foaming system, evolve into foam, effective in the topical treatment of various skin conditions.
Iodine and iodine complex preparations are widely employed as disinfectants in human and veterinary medicine. Iodine has a powerful bactericidal and fungicidal action and is also active against viruses. It is used as topical antiseptic agents for treatment of small wounds, abrasions and other skin lesions such as herpes simplex. Iodine containing compositions are used for protective treatment of a skin area to be dissected.
Iodine preparations are used in veterinary medicine as post-milking disinfecting treatment of the udders. Iodine is also effectively used for disinfection of drinking water and swimming pool water (Martindale, The extra pharmacopoeia, [28TH] edition, Eds.: Reynolds, J. E. F. and Prasad, A. B., The Pharmaceutical Press, London, 1982, pp. 862-864).
Topical iodine preparations possess counter-irritating activity in rheumatism, tenosynovitis and in inflammatory diseases of the peripheral nervous system and muscles. Additional pronounced counter-irritating activity of iodine was demonstrated against skin irritation caused by chemical and thermal stimuli. Iodine is also effective against other skin irritants such as mechlorethamine, divinylsulfone, iodoacetic acid and cantharidine (Wormser et al. Arch. Toxicol. (1997) 71, 165-170).
Molecular iodine (I2) is practically water insoluble unless iodide (sodium or potassium salts) is present in the solution to form the water-soluble ion (I3−). Iodine can be dissolved in ethanol but precipitates in the presence of water. Thus, iodine tincture (which contains ethyl alcohol and water) must also contain iodide to form I3− for proper dissolution.
Iodine formulations using other solvents or carriers are known. In some cases, these formulations are shown to have greater iodine solubility or improved iodine release. In some cases, the iodine formulations are demonstrated to be more potent as antiseptics than currently available commercial iodine preparations.
Post-exposure treatment with topical povidone (polyvinylpyrolidone)-iodine preparation has been shown to provide significant protection against mustard gas (sulfur mustard, SM)-induced skin lesions (Wormser et al. Arch. Toxicol. (1997) 71, 165-170). Studies also have shown the counter-irritating activity of povidone-iodine against thermal stimuli in humans (Wormser, Burns (1998) 24, 383). The experience with patients after accidental heat burns (mostly of grade I; caused by hot water or oil or by hot steam) has shown that topical application of povidone-iodine ointment immediately after the stimulus reduced the degree of skin lesions. The shorter the interval between stimulus and treatment the better the protection achieved.
U.S. Pat. No. 5,071,648 discloses a composition containing acetalized polyvinyl alcohol complexed with iodine, which releases free iodine in the presence of water.
WO 01/70242 discloses a composition including molecular iodine and tetraglycol (TG) that facilitates the dissolution of iodine, enhances its antiseptic effect, and remains stable in the presence of water, in contrast to other iodine solvents, such as ethanol, in which iodine precipitates after water addition. Povidone-iodine complex (PVP-I) may also be dissolved in TG or a TG water system. A pharmaceutically acceptable vehicle according to WO 01/70242 includes an oil/water or a water/oil emulsion, a solution, a suspension, a gel, an ointment, a patch, or an aerosol, preferably solutions, gels and washable ointments.
Despite many years of usage in topical therapy, iodine compositions are still restricted to the conventional list of dosage forms, consisting of water/oil emulsions, solutions, suspensions, gels, ointments, patch, or aerosols. All these preparations comprise liquid or semi-liquid substances, having continuous texture and consistency and possessing specific gravity of 0.7-1.1. Such preparations are disadvantageous, when intended to treat relatively large areas. They are even more disadvantageous when the area to be treated is sensitive, such as area with burns or open wounds, where rubbing a liquid or semi-solid formulation is difficult and painful.
Certain foamable formulations are known in the art.
U.S. Pat. No. 5,716,611 discloses a topical formulation comprising an anti-microbially effective amount of povidone-iodine and from 2% to about 30% of a water-soluble emollient comprising from about 1 to about 99% ethoxylated higher aliphatic alcohol and from about 1 to about 99% ethoxylated cholesterol derivative. The composition includes thickening agents and surfactants that provide foaming upon rubbing on the applied surface.
U.S. Pat. No. 6,258,374 provides a pharmaceutical composition for rectal or vaginal application containing at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of the composition which are such that on admixture they react to produce a physiologically acceptable gas; (ii) in at least one part of the composition a polymer stabilizer which is adapted to facilitate the formation of a water-soluble collapsible foam structure; and (iii) in at least one part of the composition a pharmaceutically active substance. One of the optional active substances is iodine.
International patent application WO 96/19921 discloses a composition having biocidal activity comprising an active agent selected from iodine or a compound or complex thereof and a polymeric solubilizing agent. The composition may be a foam.
U.S. Pat. No. 6,187,290 teaches physiologically acceptable foam including a foamable carrier separately packaged from an active ingredient. The active ingredient may be, among others, povidone-iodine. Surfactants, humectants and plasticizers may be optionally included.
U.S. Pat. No. 5,951,993 discloses a composition including a lower alcohol and water in a weight ratio of about 35:65 to 100:0, and a thickener system. The thickener system includes at least two emulsifiers, each emulsifier containing at least one hydrophobic group and at least one hydrophilic group. The composition optionally contains iodine or a complexed form of iodine. The composition is useful as a presurgical scrub replacement, a lotion or other hand preparation.
U.S. Pat. No. 5,672,634 describes a rigid, cellular PVP-I foam product, useful as an iodophor, containing about 0.1-2% cross linker and about 16-18% total inorganic iodine.
U.S. Pat. No. 5,545,401 teaches a foaming gel consisting essentially of water, povidone and iodine. In one embodiment water is added to the gel in a closed container pressurized at between 1 and 3 atmospheres with pentane so that when the mixture is returned to atmospheric pressure it spontaneously forms a foam.
U.S. Pat. No. 5,254,334 describes an anhydrous cream composition comprising (a) glycerin in an amount from about 40% to about 60% by weight based on the weight of the total composition; (b) sodium cocoyl isethionate in an amount from about 10 to about 19% by weight based on the weight of the total composition; (c) emollients in an amount from about 10 to about 40% by weight based on the weight of the total composition; and (d) sodium lauryl sulfate in an amount from about 1 to about 5% by weight based on the weight of the total composition. The composition may further comprise a foam booster or active ingredients such as PVP-iodine.
U.S. Pat. No. 4,271,149 discloses a germicidal iodine composition containing an aqueous solution of elemental iodine and at least one organic substance which slowly reacts with iodine selected from the group consisting of iodine complexing polymers, surface active agents, alcohols, polyols and water soluble solvents. The iodine composition is stable for extended storage by providing balanced sources of iodide ion in the range of about 0.025% to 0.5% and iodate ion in the range of about 0.005% to 0.2% while maintaining a pH within the range of pH 5-7. Foam stabilizers are optional components of the composition.
New topical dosage forms are desired to deliver iodine and to treat skin conditions that respond to iodine topical application. A simple-to-use breakable foam, having low specific gravity and being easily spreadable on large skin areas, is particularly desirable.
The present invention provides a foamable composition including iodine, water, a foam adjuvant, a surface-active agent and a gelling agent that is easily applied and provides high availability of iodine to the applied surface.
According to one aspect the present invention, a foamable composition includes iodine, water, a foam adjuvant, a surface active agent and a gelling agent, in the following concentrations:
about 0.1% to about 5% by weight iodine;
about 80% to about 99.6% by weight of at least one solvent;
about 0.1% to about 5% by weight of at least one foam adjuvant;
about 0.1% to about 5% by weight of at least one surface active agent; and
about 0.1% to about 5% by weight of at least one gelling agent.
The % values presented herein are provided on a weight (w/w) basis of the total composition.
The composition according to one or more embodiments of the present invention, when provided in a suitable foaming device, forms a foam that is effective in the topical treatment of various skin conditions.
According to one or more embodiments of the present invention, the composition is provided in a plastic or glass propellant free foaming dispenser and forms a breakable or collapsible foam when dispensed from the propellant free foaming dispenser.
According to one or more embodiments of the present invention, the composition further includes a liquefied or compressed gas propellant, for example, at a concentration of about 3% to about 25% of the total composition.
According to one or more embodiments of the present invention, the foamed composition has specific gravity of about 0.02 gr/ml to about 0.35 gr/ml.
According to one or more embodiments of the present invention, iodine is selected from molecular iodine and complexed iodine. Complexed iodine may be selected from cadexomer-iodine, diiodhydrin, domiodol, hydriodic acid, iodinated glycerol, iodoform, iodide and povidone-iodine
According to one or more embodiments of the present invention, the solvent is water or a water miscible organic solvent, such as a polyhydroxy compounds and poly-ethoxylated compounds. In one embodiment the composition has a water-to-water miscible organic solvent ratio of about 1:10 to about 10:1. Due to the skin irritability of lower alkyl alcohols, the water miscible compound is not a lower alkyl, e.g., C1-C5, alcohol.
In one or more embodiments, the polyhydroxy compound is selected from ethylene glycol, propylene glycol, glycerol, butanediols and isomers thereof, pentaerythritol, sorbitol, mannitol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, diethylene glycol monoethyl ether and mixtures thereof.
In one or more embodiments, the poly-ethoxylated compound is selected from polyethylene glycol, tetrahydrofurfuryl alcohol and polyethyleneglycol. The solvent can be mixtures of water, polyhydroxy compounds and/or poly-ethyoxylated compounds.
According to one or more embodiments, a surface active agent may be an anionic surface active agent, a cationic surface active agent, a nonionic surface active agent, a zwitterionic surface active agent, an amphoteric surface active agent, an ampholytic surface active agent and mixtures thereof.
In one or more embodiments, the surface-active agent includes at least a non-ionic agent. In one or more embodiments, the surface active agent is a mixture of a non-ionic surface active agent and an anionic surface active agent provided at a weight ratio of about 4:1 to about 1:4 more preferably a weight ratio of about 2:1 to about 1:2. In one or more embodiments, the surface-active agent has a HLB value higher than about 8.
According to one or more embodiments, the foam adjuvant is selected from a fatty alcohol, a fatty acid mixtures thereof, and is provided at a concentration between about 0.4% and about 2.5% of the composition.
Another aspect the present invention provides a method of treating, alleviating or preventing a human or veterinary disorder by topically administering to a surface afflicted with the disorder an effective amount of the composition according to one or more embodiments of the present invention.
The method of the invention, according to one or more embodiments, provides for the prophylaxis, or treatment of or alleviation of the symptoms of a variety of infectious dermatological disorders, including for example heat burns, chemical burns, infections, wounds, cuts and ulcers and radioactive radiation damage, and burns and infections resulting from chemical and biological warfare agents.
The invention is described with reference to the FIGURE, which is provided for the purpose of illustration only and is not intended to be limiting of the invention.
The FIGURE is an illustration of a foam dispenser used in one or more embodiments of the present invention.
Composition
According to one aspect, the present invention provides a foamable composition of matter includes iodine, water, a foam adjuvant, a surface active agent and a gelling agent, in the following concentrations, reported as percent by weight:
iodine: about 0.1% to about 5%;
at least one solvent: about 80% to about 99.6%;
at least one foam adjuvant: about 0.1% to about 5%;
at least one surface active agent: about 0.1% to about 5%; and
at least one gelling agent: about 0.1% to about 5%.
The % values presented herein are provided on a weight (w/w) basis of the total composition.
The composition according to one or more embodiments of the present invention is applied to the surface as a foam. That is, the foamed composition is applied to the substrate and is not generated by rubbing or lathering. The foamed composition, according to one or more embodiments of the present invention, is dispensed from a glass or plastic container that dispenses foam in the absence of a gas or liquid propellant.
Alternatively, the composition of the present invention further includes a liquefied or compressed gas propellant at a concentration of about 3% to about 25% of the total composition. Examples of suitable propellants include volatile hydrocarbons such as butane, propane, isobutane or mixtures thereof, and fluorocarbon gases.
The foamed composition, according to one or more embodiments of the present invention, is of exceptionally low specific gravity, for example, the foamed composition has a specific gravity in the range of about 0.02 gr/ml to about 0.35 gr/ml. Although of low specific gravity, the foam is highly stable and will remain without collapse for several minutes. Nonetheless, the foam collapses readily upon application of mild shear stress. Low specific gravity, high foam stability and ready collapsibility all contribute to a foamed composition that is easily applied and administered over large areas without rubbing or chaffing of the affected area.
Iodine
“Iodine” and “iodine species” include iodine in its native form or released from a compound. In its native form, iodine (I2) is provided as bluish-black crystals, having density of about 5 g/cm3. When used as is, the iodine concentration in the total composition ranges between 0.1% and 5% and more preferably, between 0.5% and 1.5%. In other embodiments of the present invention molecular iodine is released from an iodine-containing and/or producing compound. Non-limiting examples of such compounds include cadexomer-iodine, diiodhydrin, domiodol, hydriodic acid, iodinated glycerol, iodide, iodoform, and povidone-iodine. When provided as an iodine-containing and/or producing compound, the compound concentration in the total composition is calculated to achieve a final iodine concentration ranging between about 0.1% and 5% by weight and more preferably, between about 0.5% and about 1.5% by weight.
Solvent
According to one or more embodiments, the composition includes about 80% to about 99.6% solvent, and typically includes water. Iodine is not highly soluble in water and thus, formulation stability and effectiveness is limited. In a one or more embodiments of the present invention, the solvent includes water and a water miscible organic solvent, which by way of non-limiting examples, is a polyhydroxy compound and/or a poly-ethoxylated compound.
Suitable polyhydroxy solvents (polyols) include small organic molecules having two or more hydroxy groups on their carbon skeleton, such as ethylene glycol, propylene glycol, glycerol, butanediols and isomers thereof, pentaerythritol, sorbitol, mannitol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, diethylene glycol monoethyl ether (Transcutol®) and mixtures thereof.
Poly-ethoxylated compounds can enhance the effectiveness of iodine significantly by dissolving the I2. Examples of suitable poly-ethoxylated compounds include polyethylene glycol (e.g., PEG 400), tetrahydrofurfuryl alcohol polyethyleneglycol ether (glycofurol, tetraglycol (TG)). Among the above-mentioned water miscible solvents, suitable compounds include transcutol, polyethylene glycol and TG and mixtures thereof. The ratio between water and the water miscible solvents is in the range of about 1:10 to about 10:1. In one or more embodiments, the ratio is between about 1:4 and about 4:1. Due to the skin irritability of lower alkyl (C1-C5) alcohols, and the tendency of such alcohols to impair the natural skin barrier by dissolving and removing the oily components of the skin, lower alkyl alcohols are not included as a miscible organic solvent.
Foam Adjuvant
A foam adjuvant is included in the composition to improve the stability and reduce the specific gravity of the foamed composition. In one or more embodiments of the present invention, foam adjuvants include fatty alcohols, fatty acids, and mixtures thereof. The foam adjuvant can include at least one fatty alcohol and at least one fatty acid.
Suitable fatty alcohols include alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). The concentration of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains. Fatty alcohols that are derived from beeswax, including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvants according to the present invention. The concentration of the fatty alcohol required to support the foam system is inversely related to the length of its carbon chains.
Suitable fatty acids include acids having 16 or more carbons in its carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof. As for fatty alcohols, the concentration of fatty acids required to support the foam system is inversely proportionate to carbon chain length.
Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond. A further class of foam adjuvant agent includes a long chain fatty alcohol or fatty acid, wherein the carbon atom chain is branched. The carbon chain of the fatty acid or fatty alcohol can be substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
The foam adjuvant of the present invention may include a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and alcohols in any proportion. The total amount of foam adjuvants is about 0.1% to about 5% (w/w) of the carrier mass, and typically, the total amount is about 0.4% to about 2.5% (w/w) of the carrier mass.
In one or more embodiments of the present invention, a fatty alcohol possesses a therapeutic properties per se. Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, anti infective, anti-proliferative and anti-inflammatory properties (U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc. are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics. Thus, the iodine foamable composition of the present invention, containing the foam adjuvant provides a synergistic therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
Surface-active Agent
According to one or more embodiments of the present invention, the surface-active agent includes any agent linking oil and water in the composition, e.g., the agent can be a surfactant. In one or more embodiments of the present invention, the composition includes about 0.1% to about 5% of the surface-active agent.
Suitable surface-active agents include anionic, cationic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the pharmaceutical and cosmetic formulation art. Non-limiting examples of useful surfactants include sucrose esters, sorbitan esters, PEG esters or ethers of fatty chains, mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines (e.g., cocamidopropyl betaine and lauramidopropyl betaine), which are known to contribute to foam stability (foam boosters).
While any surface-active agent may be used in the present invention, a surface-active agent having an HLB (hydrophilic-lipophilic balance) higher than 8 is used in one or more embodiments of the present invention.
Non-ionic surfactants are particularly well suited as surface-active agents. A combination of a non-ionic surfactant and an anionic surfactant (such as sodium lauryl sulfate) may also be used. A ratio of non-ionic surfactant to anionic surfactant between around 4:1 and about 1:4, or between about 2:1 and about 1:2, provides a foam, which upon rubbing onto the skin collapses easily, to allow facile spreading and absorption. A surface-active agent mix is even further improved when a foam stabilizing surfactant, such as cocamidopropyl betaine, is added.
Gelling Agent
In one or more embodiments of the present invention, the composition includes about 0.1% to about 5% of a gelling agent. Suitable gelling agents include, in a non-limiting manner, naturally-occurring polymeric materials such as locust bean gum, guar gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum, sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose), hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars and the like and synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like.
Also useful herein are gelling agents such as the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol® resins. These resins include a colloidal water-soluble polyalkenyl polyether cross linked polymer of acrylic acid cross linked with from 0.75% to 2% of a cross linking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981. Carbopol 934 is a water-soluble polymer of acrylic acid cross linked with about 1% of polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
Methods of Evolving and Releasing the Foam
Any customary method of evolving foam is applicable according to the present invention. By way of example, in one optional configuration, the composition according to one or more embodiments of the present invention is preferably placed, together with a liquefied or compressed gas propellant in the amount of about 3% to about 25% of the total composition, in an aerosol container. Upon pressing the actuator, a breakable foam, suitable for topical administration is released. Due to the oxidizing nature of iodine, containers that are coated with highly durable lacquers of coatings are used.
In an alternative exemplary configuration, the composition according to one or more embodiments of the present invention is placed in a plastic or glass container, equipped with a foaming dispenser that works without gas propellants. Such dispensers are described, for example, in U.S. Pat. No. 6,536,629, in which the dispenser includes a container and a dispensing assembly coupled in liquid-tight manner. The dispensing assembly can have a liquid pump with a liquid inlet and a liquid outlet. An exemplary foam dispenser is shown in the FIGURE.
Foam Characteristics
The foam that is released from the aerosol container or from the propellant-free foaming dispenser is well aerated. It has specific gravity of about 0.02 gr/ml to about 0.35 gr/ml. When applied onto a surface, specifically a skin surface, and rubbed gently, it spreads easily over the area, without the need of extensive rubbing.
A foam composition of one or more embodiments of the present invention is advantageous over formulation options. A foamed composition may possess one or more of the following properties. The foam is lightweight and thus, economical. The foam is easily spreadable, allowing treatment of large areas such as the arms, back, legs and the breast. The flow properties provide a foam that spreads effectively into folds and wrinkles, providing uniform distribution of the active agent without the need of extensive rubbing and absorbs into the skin. The low specific gravity, e.g., fluffy, nature of the foam renders application of the foam on large skin areas very easy, irritation-free and painless.
Foam Applications
The compositions according to one or more embodiments of the present invention are useful in the various medicinal disciplines including human and veterinary medicine. More generally, the compositions according to the present invention can be used in situations where use of iodine is preferred including, but not limited to, medicine, industrial processes, diagnostics and environmental purposes.
Specifically, the compositions according to one or more embodiments of the present invention are useful as antiseptic compositions. The compositions may be further used to protect from, prevent, alleviate the symptoms of or cure a variety of infectious dermatological disorders, including: bacterial Infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma; fungal infections including dermatophyte infections, yeast infections; parasitic infections including scabies, pediculosis, creeping eruption and viral infections.
The treatment of heat burns, chemical burns (caused by chemicals such as acids, bases, caustic materials and warfare chemicals), wounds, cuts and ulcers using the composition according to one or more embodiments of the present invention is particularly advantageous. Upon application, the foam spreads easily, covering the surface of the affected area, and without causing pain.
The composition of the invention is also useful as a protectant in case of exposure to radiation and radioactive isotopes.
According to another aspect the present invention provides a method of treating, alleviating or preventing a human or veterinary disorder by topically administering to a surface afflicted with the disorder an effective amount of the composition including:
about 0.1% to about 5% by weight iodine;
about 80% to about 99.6% by weight of at least one solvent;
about 0.1% to about 5% by weight of at least one foam adjuvant;
about 0.1% to about 5% by weight of at least one surface active agent; and
about 0.1% to about 5% by weight of at least one gelling agent.
The present invention provides for the prophylaxis, or treatment of or alleviating the symptoms of a variety of infectious dermatological disorders, including heat burns, chemical burns, infections, wounds, cuts and ulcers and radioactive radiation damage, and burns and infections resulting from chemical and biological warfare agents.
While the invention will now be described in connection with certain preferred embodiments in the following examples so that aspects thereof may be more fully understood and appreciated, it is not intended to limit the invention to these particular embodiments. On the contrary, it is intended to cover all alternatives, modifications and equivalents as may be included within the scope of the invention as defined by the appended claims. Thus, the following examples serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purposes of illustrative discussion of preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of formulation procedures as well as of the principles and conceptual aspects of the invention.
The table below lists the components of the foamable composition.
Iodine was dissolved in a mixture of glycofurol and stearyl alcohol and the mixture was heated to ˜60 C until homogeneity was obtained. Methocel was dispersed in one third portion of water, preheated to 80° C., and sucrose ester was added. The remaining two-third portion of water at room temperature was added under vigorous stirring; and xanthan gum and sodium lauryl sulfate and cocamidopropyl betaine were added mixing continuously for 15 minutes under vigorous stirring. The iodine mixture was added carefully to aqueous mixture and was stirred for an additional 5 minutes for complete homogeneity. The resultant product was cooled to room temperature and filled into bottles.
The composition of Example 1 (50 ml) at ambient temperature was added to a 125 ml aerosol container, the container was sealed with an aerosol valve and a butane/propane propellant (about 16% of the composition mass) was compressed into the container. Upon pressing the aerosol valve, a rich foam having specific gravity of about 0.1 gr/ml was released.
The composition of Example 1 (50 ml) at ambient temperature was added to a 125 ml container, equipped with a foaming dispenser that works without gas propellants (Airspray International Inc., 3768 Park Central Blvd. North, Pompano Beach, Fla. 33064, USA). Upon pressing the aerosol valve, rich foam having specific gravity of about 0.1 gr/ml to about 0.3 gr/ml was released.
This application is a continuation of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 12/499,609, filed Jul. 8, 2009, entitled “Foamable Iodine Compositions,” which claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 10/835,359, filed Apr. 28, 2004, entitled “Foamable Iodine Compositions,” which claims the benefit of priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/466,094, filed Apr. 28, 2003, entitled “Foamable Iodine Compositions,” the entire contents of all of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1159250 | Moulton | Nov 1915 | A |
1666684 | Carstens | Apr 1928 | A |
1924972 | Beckert | Aug 1933 | A |
2085733 | Bird | Jul 1937 | A |
2390921 | Clark | Dec 1945 | A |
2524590 | Boe | Oct 1950 | A |
2586287 | Apperson | Feb 1952 | A |
2617754 | Neely | Nov 1952 | A |
2767712 | Waterman | Oct 1956 | A |
2968628 | Reed | Jan 1961 | A |
3004894 | Johnson et al. | Oct 1961 | A |
3062715 | Reese et al. | Nov 1962 | A |
3067784 | Gorman | Dec 1962 | A |
3092255 | Hohman | Jun 1963 | A |
3092555 | Horn | Jun 1963 | A |
3141821 | Compeau | Jul 1964 | A |
3142420 | Gawthrop | Jul 1964 | A |
3144386 | Brightenback | Aug 1964 | A |
3149543 | Naab | Sep 1964 | A |
3154075 | Weckesser | Oct 1964 | A |
3178352 | Erickson | Apr 1965 | A |
3236457 | Kennedy et al. | Feb 1966 | A |
3244589 | Sunnen | Apr 1966 | A |
3252859 | Silver | May 1966 | A |
3261695 | Sienkiewicz | Jul 1966 | A |
3263867 | Lehmann | Aug 1966 | A |
3263869 | Corsette | Aug 1966 | A |
3298919 | Bishop et al. | Jan 1967 | A |
3301444 | Wittke | Jan 1967 | A |
3303970 | Breslau et al. | Feb 1967 | A |
3330730 | Hernandez | Jul 1967 | A |
3333333 | Noack | Aug 1967 | A |
3346451 | Collins et al. | Oct 1967 | A |
3366494 | Bower et al. | Jan 1968 | A |
3369034 | Chalmers | Feb 1968 | A |
3377004 | Wittke | Apr 1968 | A |
3384541 | Clark et al. | May 1968 | A |
3395214 | Mummert | Jul 1968 | A |
3395215 | Schubert | Jul 1968 | A |
3401849 | Weber, III | Sep 1968 | A |
3419658 | Sanders | Dec 1968 | A |
3456052 | Gordon | Jul 1969 | A |
3527559 | Sliwinski | Sep 1970 | A |
3540448 | Sunnen | Nov 1970 | A |
3559890 | Brooks et al. | Feb 1971 | A |
3561262 | Borucki | Feb 1971 | A |
3563098 | Weber, III | Feb 1971 | A |
3574821 | Pfirrmann | Apr 1971 | A |
3577518 | Shepherd | May 1971 | A |
3667461 | Zamarra | Jun 1972 | A |
3751562 | Nichols | Aug 1973 | A |
3770648 | Mackles | Nov 1973 | A |
3787566 | Gauvreau | Jan 1974 | A |
3819524 | Schubert et al. | Jun 1974 | A |
3841525 | Siegel | Oct 1974 | A |
3849580 | Weinstein et al. | Nov 1974 | A |
3865275 | De Nunzio | Feb 1975 | A |
3866800 | Schmitt | Feb 1975 | A |
3882228 | Boncey et al. | May 1975 | A |
3886084 | Vassiliades | May 1975 | A |
3890305 | Weber et al. | Jun 1975 | A |
3912665 | Spitzer et al. | Oct 1975 | A |
3923970 | Breuer | Dec 1975 | A |
3929985 | Webb, Jr. | Dec 1975 | A |
3952916 | Phillips | Apr 1976 | A |
3959160 | Horsler et al. | May 1976 | A |
3962150 | Viola | Jun 1976 | A |
3963833 | DeSalva et al. | Jun 1976 | A |
3966090 | Prussin et al. | Jun 1976 | A |
3966632 | Colliopoulos et al. | Jun 1976 | A |
3970219 | Spitzer et al. | Jul 1976 | A |
3970584 | Hart et al. | Jul 1976 | A |
3993224 | Harrison | Nov 1976 | A |
3997467 | Jederstrom | Dec 1976 | A |
4001391 | Feinstone et al. | Jan 1977 | A |
4001442 | Stahlberger et al. | Jan 1977 | A |
4018396 | Shoemaker et al. | Apr 1977 | A |
4019657 | Spitzer et al. | Apr 1977 | A |
4083974 | Turi | Apr 1978 | A |
4102995 | Hebborn | Jul 1978 | A |
4110426 | Barnhurst et al. | Aug 1978 | A |
4124149 | Spitzer et al. | Nov 1978 | A |
4145411 | Mende | Mar 1979 | A |
4151272 | Geary et al. | Apr 1979 | A |
4160827 | Cho et al. | Jul 1979 | A |
4213979 | Levine | Jul 1980 | A |
4214000 | Papa | Jul 1980 | A |
4226344 | Booth et al. | Oct 1980 | A |
4229432 | Geria | Oct 1980 | A |
4230701 | Holick et al. | Oct 1980 | A |
4241048 | Durbak et al. | Dec 1980 | A |
4241149 | Labes et al. | Dec 1980 | A |
4252787 | Sherman et al. | Feb 1981 | A |
4254104 | Suzuki et al. | Mar 1981 | A |
4268499 | Keil | May 1981 | A |
4271149 | Winicov et al. | Jun 1981 | A |
4292250 | DeLuca et al. | Sep 1981 | A |
4292326 | Nazzaro-Porro et al. | Sep 1981 | A |
4299826 | Luedders | Nov 1981 | A |
4305936 | Klein | Dec 1981 | A |
4309995 | Sacco | Jan 1982 | A |
4310510 | Sherman et al. | Jan 1982 | A |
4323694 | Scala, Jr. | Apr 1982 | A |
4325939 | Shah | Apr 1982 | A |
4329990 | Sneider | May 1982 | A |
4335120 | Holick et al. | Jun 1982 | A |
4352808 | Rane et al. | Oct 1982 | A |
4385161 | Caunt et al. | May 1983 | A |
4386104 | Nazzaro-Porro | May 1983 | A |
4393066 | Garrett et al. | Jul 1983 | A |
4427670 | Ofuchi et al. | Jan 1984 | A |
4439416 | Cordon et al. | Mar 1984 | A |
4439441 | Hallesy et al. | Mar 1984 | A |
4440320 | Wernicke | Apr 1984 | A |
4447486 | Hoppe et al. | May 1984 | A |
4469674 | Shah et al. | Sep 1984 | A |
4508705 | Chaudhuri et al. | Apr 1985 | A |
4522948 | Walker | Jun 1985 | A |
4529601 | Broberg et al. | Jul 1985 | A |
4529605 | Lynch et al. | Jul 1985 | A |
4552872 | Cooper et al. | Nov 1985 | A |
4574052 | Gupte et al. | Mar 1986 | A |
4576961 | Lorck et al. | Mar 1986 | A |
4595526 | Lai | Jun 1986 | A |
4603812 | Stoesser et al. | Aug 1986 | A |
4627973 | Moran et al. | Dec 1986 | A |
4628063 | Haines et al. | Dec 1986 | A |
4661524 | Thomson et al. | Apr 1987 | A |
4672078 | Sakai et al. | Jun 1987 | A |
4673569 | Shernov et al. | Jun 1987 | A |
4678463 | Millar | Jul 1987 | A |
4701320 | Hasegawa et al. | Oct 1987 | A |
4725609 | Kull, Jr. et al. | Feb 1988 | A |
4738396 | Doi et al. | Apr 1988 | A |
4741855 | Grote et al. | May 1988 | A |
4752465 | Mackles | Jun 1988 | A |
4770634 | Pellico | Sep 1988 | A |
4780309 | Geria et al. | Oct 1988 | A |
4784842 | London et al. | Nov 1988 | A |
4792062 | Goncalves | Dec 1988 | A |
4798682 | Ansmann | Jan 1989 | A |
4804674 | Curtis-Prior et al. | Feb 1989 | A |
4806262 | Snyder | Feb 1989 | A |
4808388 | Beutler et al. | Feb 1989 | A |
4822613 | Rodero | Apr 1989 | A |
4822614 | Rodero | Apr 1989 | A |
4826048 | Skorka et al. | May 1989 | A |
4827378 | Gillan et al. | May 1989 | A |
4828837 | Uster et al. | May 1989 | A |
4836217 | Fischer et al. | Jun 1989 | A |
4837019 | Georgalas et al. | Jun 1989 | A |
4837378 | Borgman | Jun 1989 | A |
4844902 | Grohe | Jul 1989 | A |
4847068 | Dole et al. | Jul 1989 | A |
4849117 | Bronner et al. | Jul 1989 | A |
4855294 | Patel et al. | Aug 1989 | A |
4863900 | Pollock et al. | Sep 1989 | A |
4867967 | Crutcher | Sep 1989 | A |
4873078 | Edmundson et al. | Oct 1989 | A |
4874794 | Katz | Oct 1989 | A |
4877805 | Kligman | Oct 1989 | A |
4885282 | Thornfeldt | Dec 1989 | A |
4897262 | Nandagiri et al. | Jan 1990 | A |
4902281 | Avoy | Feb 1990 | A |
4906453 | Tsoucalas | Mar 1990 | A |
4913893 | Varco et al. | Apr 1990 | A |
4919934 | Deckner et al. | Apr 1990 | A |
4954487 | Cooper et al. | Sep 1990 | A |
4956049 | Bernheim et al. | Sep 1990 | A |
4957732 | Grollier et al. | Sep 1990 | A |
4963351 | Weston | Oct 1990 | A |
4966779 | Kirk | Oct 1990 | A |
4970067 | Panandiker et al. | Nov 1990 | A |
4975466 | Bottcher et al. | Dec 1990 | A |
4981367 | Brazelton | Jan 1991 | A |
4981677 | Thau | Jan 1991 | A |
4981679 | Briggs et al. | Jan 1991 | A |
4981845 | Pereira et al. | Jan 1991 | A |
4985459 | Sunshine et al. | Jan 1991 | A |
4992478 | Geria | Feb 1991 | A |
4993496 | Riedle et al. | Feb 1991 | A |
5002540 | Brodman et al. | Mar 1991 | A |
5002680 | Schmidt et al. | Mar 1991 | A |
5007556 | Lover | Apr 1991 | A |
5013297 | Cattanach | May 1991 | A |
5015471 | Birtwistle et al. | May 1991 | A |
5019375 | Tanner et al. | May 1991 | A |
5034220 | Helioff et al. | Jul 1991 | A |
5035895 | Shibusawa et al. | Jul 1991 | A |
5053228 | Mori et al. | Oct 1991 | A |
5071648 | Rosenblatt | Dec 1991 | A |
5071881 | Parfondry et al. | Dec 1991 | A |
5073371 | Turner et al. | Dec 1991 | A |
5082651 | Healey et al. | Jan 1992 | A |
5087618 | Bodor | Feb 1992 | A |
5089252 | Grollier et al. | Feb 1992 | A |
5091111 | Neumiller | Feb 1992 | A |
5094853 | Hagarty | Mar 1992 | A |
5100917 | Flynn et al. | Mar 1992 | A |
5104645 | Cardin et al. | Apr 1992 | A |
5112359 | Murphy et al. | May 1992 | A |
5114718 | Damani | May 1992 | A |
5122519 | Ritter | Jun 1992 | A |
5130121 | Kopolow et al. | Jul 1992 | A |
5133972 | Ferrini et al. | Jul 1992 | A |
5135915 | Czarniecki et al. | Aug 1992 | A |
5137714 | Scott | Aug 1992 | A |
5143717 | Davis | Sep 1992 | A |
5156765 | Smrt | Oct 1992 | A |
5164357 | Bartman et al. | Nov 1992 | A |
5164367 | Pickart | Nov 1992 | A |
5167950 | Lins | Dec 1992 | A |
5171577 | Griat et al. | Dec 1992 | A |
5196405 | Packman | Mar 1993 | A |
5204093 | Victor | Apr 1993 | A |
5208031 | Kelly | May 1993 | A |
5217707 | Szabo et al. | Jun 1993 | A |
5219877 | Shah et al. | Jun 1993 | A |
5221696 | Ke et al. | Jun 1993 | A |
5230897 | Griffin et al. | Jul 1993 | A |
5236707 | Stewart, II | Aug 1993 | A |
5252246 | Ding et al. | Oct 1993 | A |
5254334 | Ramirez et al. | Oct 1993 | A |
5262407 | Leveque et al. | Nov 1993 | A |
5266592 | Grub et al. | Nov 1993 | A |
5279819 | Hayes | Jan 1994 | A |
5286475 | Louvet et al. | Feb 1994 | A |
5300286 | Gee | Apr 1994 | A |
5301841 | Fuchs | Apr 1994 | A |
5308643 | Osipow et al. | May 1994 | A |
5314904 | Egidio et al. | May 1994 | A |
5322683 | Mackles et al. | Jun 1994 | A |
5326557 | Glover et al. | Jul 1994 | A |
5344051 | Brown | Sep 1994 | A |
5346135 | Vincent | Sep 1994 | A |
5352437 | Nakagawa et al. | Oct 1994 | A |
5369131 | Poli et al. | Nov 1994 | A |
5378451 | Gorman et al. | Jan 1995 | A |
5378730 | Lee et al. | Jan 1995 | A |
5380761 | Szabo et al. | Jan 1995 | A |
5384308 | Henkin | Jan 1995 | A |
5385943 | Nazzaro-Porro | Jan 1995 | A |
5389676 | Michaels | Feb 1995 | A |
5397312 | Rademaker et al. | Mar 1995 | A |
5398846 | Corba et al. | Mar 1995 | A |
5399205 | Shinohara et al. | Mar 1995 | A |
5411992 | Eini et al. | May 1995 | A |
5422361 | Munayyer et al. | Jun 1995 | A |
5429815 | Faryniarz et al. | Jul 1995 | A |
5435996 | Glover et al. | Jul 1995 | A |
5447725 | Damani et al. | Sep 1995 | A |
5449520 | Frigerio et al. | Sep 1995 | A |
5451404 | Furman | Sep 1995 | A |
5482965 | Rajadhyaksha | Jan 1996 | A |
5491245 | Gruning et al. | Feb 1996 | A |
5500211 | George et al. | Mar 1996 | A |
5508033 | Briand et al. | Apr 1996 | A |
5512555 | Waldstreicher | Apr 1996 | A |
5514367 | Lentini et al. | May 1996 | A |
5514369 | Salka et al. | May 1996 | A |
5520918 | Smith | May 1996 | A |
5523078 | Baylin | Jun 1996 | A |
5527534 | Myhling | Jun 1996 | A |
5527822 | Scheiner | Jun 1996 | A |
5529770 | McKinzie et al. | Jun 1996 | A |
5531703 | Skwarek et al. | Jul 1996 | A |
5534261 | Rodgers et al. | Jul 1996 | A |
5536743 | Borgman | Jul 1996 | A |
5540853 | Trinh et al. | Jul 1996 | A |
5545401 | Shanbrom | Aug 1996 | A |
5567420 | McEleney et al. | Oct 1996 | A |
5576016 | Amselem et al. | Nov 1996 | A |
5578315 | Chien et al. | Nov 1996 | A |
5585104 | Ha et al. | Dec 1996 | A |
5589157 | Hatfield | Dec 1996 | A |
5589515 | Suzuki et al. | Dec 1996 | A |
5597560 | Bergamini et al. | Jan 1997 | A |
5603940 | Candau et al. | Feb 1997 | A |
5605679 | Hansenne et al. | Feb 1997 | A |
5608119 | Amano et al. | Mar 1997 | A |
5611463 | Favre | Mar 1997 | A |
5612056 | Jenner et al. | Mar 1997 | A |
5613583 | Kono et al. | Mar 1997 | A |
5613623 | Hildebrandt | Mar 1997 | A |
5614171 | Clavenna et al. | Mar 1997 | A |
5614178 | Bloom et al. | Mar 1997 | A |
5635469 | Fowler et al. | Jun 1997 | A |
5641480 | Vermeer | Jun 1997 | A |
5643600 | Mathur | Jul 1997 | A |
5645842 | Gruning et al. | Jul 1997 | A |
5650554 | Moloney | Jul 1997 | A |
5658575 | Ribier et al. | Aug 1997 | A |
5658749 | Thornton | Aug 1997 | A |
5658956 | Martin et al. | Aug 1997 | A |
5663208 | Martin | Sep 1997 | A |
5672634 | Tseng et al. | Sep 1997 | A |
5679324 | Lisboa et al. | Oct 1997 | A |
5683710 | Akemi et al. | Nov 1997 | A |
5686088 | Mitra et al. | Nov 1997 | A |
5693258 | Tonomura et al. | Dec 1997 | A |
5695551 | Buckingham et al. | Dec 1997 | A |
5700396 | Suzuki et al. | Dec 1997 | A |
5716611 | Oshlack et al. | Feb 1998 | A |
5716621 | Bello | Feb 1998 | A |
5719122 | Chiodini et al. | Feb 1998 | A |
5719197 | Kanios et al. | Feb 1998 | A |
5725872 | Stamm et al. | Mar 1998 | A |
5725874 | Oda | Mar 1998 | A |
5730964 | Waldstreicher | Mar 1998 | A |
5733558 | Breton et al. | Mar 1998 | A |
5733572 | Unger et al. | Mar 1998 | A |
5747049 | Tominaga | May 1998 | A |
5753241 | Ribier et al. | May 1998 | A |
5753245 | Fowler et al. | May 1998 | A |
5759520 | Sachetto | Jun 1998 | A |
5759579 | Singh et al. | Jun 1998 | A |
5767104 | Bar-Shalom et al. | Jun 1998 | A |
5773410 | Yamamoto | Jun 1998 | A |
5783202 | Tomlinson et al. | Jul 1998 | A |
5788664 | Scalise | Aug 1998 | A |
5792448 | Dubief et al. | Aug 1998 | A |
5792922 | Moloney et al. | Aug 1998 | A |
5797955 | Walters | Aug 1998 | A |
5804546 | Hall et al. | Sep 1998 | A |
5817322 | Xu et al. | Oct 1998 | A |
5824650 | De Lacharriere et al. | Oct 1998 | A |
5833960 | Gers-Barlag et al. | Nov 1998 | A |
5833961 | Siegfried et al. | Nov 1998 | A |
5837270 | Burgess | Nov 1998 | A |
5840744 | Borgman | Nov 1998 | A |
5840771 | Oldham et al. | Nov 1998 | A |
5843411 | Hernandez et al. | Dec 1998 | A |
5846983 | Sandborn et al. | Dec 1998 | A |
5849042 | Lim et al. | Dec 1998 | A |
5856452 | Moloney et al. | Jan 1999 | A |
5858371 | Singh et al. | Jan 1999 | A |
5865347 | Welschoff | Feb 1999 | A |
5866040 | Nakama et al. | Feb 1999 | A |
5869529 | Sintov et al. | Feb 1999 | A |
5871720 | Gutierrez et al. | Feb 1999 | A |
5877216 | Place et al. | Mar 1999 | A |
5879469 | Avram et al. | Mar 1999 | A |
5881493 | Restive | Mar 1999 | A |
5885581 | Massand | Mar 1999 | A |
5889028 | Sandborn et al. | Mar 1999 | A |
5889054 | Yu et al. | Mar 1999 | A |
5891458 | Britton et al. | Apr 1999 | A |
5902574 | Stoner et al. | May 1999 | A |
5902789 | Stoltz | May 1999 | A |
5905092 | Osborne et al. | May 1999 | A |
5910382 | Goodenough et al. | Jun 1999 | A |
5911981 | Dahms et al. | Jun 1999 | A |
5912007 | Pan et al. | Jun 1999 | A |
5914122 | Otterbeck et al. | Jun 1999 | A |
5914310 | Li et al. | Jun 1999 | A |
5922331 | Mausner | Jul 1999 | A |
5925669 | Katz et al. | Jul 1999 | A |
5948682 | Moloney | Sep 1999 | A |
5951544 | Konwitz | Sep 1999 | A |
5951989 | Heymann | Sep 1999 | A |
5951993 | Scholz et al. | Sep 1999 | A |
5952373 | Lanzendorfer et al. | Sep 1999 | A |
5952392 | Katz et al. | Sep 1999 | A |
5955414 | Brown et al. | Sep 1999 | A |
5959161 | Kenmochi et al. | Sep 1999 | A |
5961957 | McAnalley | Oct 1999 | A |
5961998 | Arnaud et al. | Oct 1999 | A |
5972310 | Sachetto | Oct 1999 | A |
5976555 | Liu et al. | Nov 1999 | A |
5980904 | Leverett et al. | Nov 1999 | A |
5990100 | Rosenberg et al. | Nov 1999 | A |
5993846 | Friedman et al. | Nov 1999 | A |
6001341 | Genova et al. | Dec 1999 | A |
6006948 | Auer | Dec 1999 | A |
6019967 | Breton et al. | Feb 2000 | A |
6024942 | Tanner et al. | Feb 2000 | A |
6030630 | Fleury et al. | Feb 2000 | A |
6033647 | Touzan et al. | Mar 2000 | A |
6039936 | Restle et al. | Mar 2000 | A |
6042848 | Lawyer et al. | Mar 2000 | A |
6045779 | Mueller et al. | Apr 2000 | A |
6071536 | Suzuki et al. | Jun 2000 | A |
6075056 | Quigley, Jr. et al. | Jun 2000 | A |
6080394 | Lin et al. | Jun 2000 | A |
6087317 | Gee | Jul 2000 | A |
6090772 | Kaiser et al. | Jul 2000 | A |
6093408 | Hasenoehrl et al. | Jul 2000 | A |
6096756 | Crain et al. | Aug 2000 | A |
6110477 | Hernandez et al. | Aug 2000 | A |
6110966 | Pollock | Aug 2000 | A |
6113888 | Castro et al. | Sep 2000 | A |
6116466 | Gueret | Sep 2000 | A |
6121210 | Taylor | Sep 2000 | A |
6126920 | Jones et al. | Oct 2000 | A |
6140355 | Egidio et al. | Oct 2000 | A |
6146645 | Deckers et al. | Nov 2000 | A |
6146664 | Siddiqui | Nov 2000 | A |
6162834 | Sebillotte-Arnaud et al. | Dec 2000 | A |
6165455 | Torgerson et al. | Dec 2000 | A |
6168576 | Reynolds | Jan 2001 | B1 |
6171347 | Kunz et al. | Jan 2001 | B1 |
6180669 | Tamarkin | Jan 2001 | B1 |
6183762 | Deckers et al. | Feb 2001 | B1 |
6186367 | Harrold | Feb 2001 | B1 |
6187290 | Gilchrist et al. | Feb 2001 | B1 |
6189810 | Nerushai et al. | Feb 2001 | B1 |
6190365 | Abbott et al. | Feb 2001 | B1 |
6204285 | Fabiano et al. | Mar 2001 | B1 |
6210656 | Touzan et al. | Apr 2001 | B1 |
6210742 | Deckers et al. | Apr 2001 | B1 |
6214318 | Osipow et al. | Apr 2001 | B1 |
6214788 | Velazco et al. | Apr 2001 | B1 |
6221381 | Shelford et al. | Apr 2001 | B1 |
6221823 | Crisanti et al. | Apr 2001 | B1 |
6224888 | Vatter et al. | May 2001 | B1 |
6231837 | Stroud et al. | May 2001 | B1 |
6232315 | Shafer et al. | May 2001 | B1 |
6251369 | Stoltz | Jun 2001 | B1 |
6258374 | Friess et al. | Jul 2001 | B1 |
6271295 | Powell et al. | Aug 2001 | B1 |
6274150 | Simonnet et al. | Aug 2001 | B1 |
6287546 | Reich et al. | Sep 2001 | B1 |
6294550 | Place et al. | Sep 2001 | B1 |
6299023 | Arnone | Oct 2001 | B1 |
6299032 | Hamilton | Oct 2001 | B1 |
6299900 | Reed et al. | Oct 2001 | B1 |
6305578 | Hildebrandt et al. | Oct 2001 | B1 |
6306841 | Place et al. | Oct 2001 | B1 |
6308863 | Harman | Oct 2001 | B1 |
6319913 | Mak et al. | Nov 2001 | B1 |
6328950 | Franzke et al. | Dec 2001 | B1 |
6328982 | Shiroyama et al. | Dec 2001 | B1 |
6333362 | Lorant | Dec 2001 | B1 |
6335022 | Simonnet et al. | Jan 2002 | B1 |
6341717 | Auer | Jan 2002 | B2 |
6344218 | Dodd et al. | Feb 2002 | B1 |
6348229 | Eini et al. | Feb 2002 | B1 |
6358541 | Goodman | Mar 2002 | B1 |
6364854 | Ferrer et al. | Apr 2002 | B1 |
6372234 | Deckers et al. | Apr 2002 | B1 |
6375960 | Simonnet et al. | Apr 2002 | B1 |
6383471 | Chen et al. | May 2002 | B1 |
6395258 | Steer | May 2002 | B1 |
6395300 | Straub et al. | May 2002 | B1 |
6403061 | Candau et al. | Jun 2002 | B1 |
6403069 | Chopra et al. | Jun 2002 | B1 |
6410036 | De Rosa et al. | Jun 2002 | B1 |
6423323 | Neubourg | Jul 2002 | B2 |
6428772 | Singh et al. | Aug 2002 | B1 |
6433003 | Bobrove et al. | Aug 2002 | B1 |
6433024 | Popp et al. | Aug 2002 | B1 |
6433033 | Isobe et al. | Aug 2002 | B1 |
6437006 | Yoon et al. | Aug 2002 | B1 |
6440429 | Torizuka et al. | Aug 2002 | B1 |
6447801 | Salafsky et al. | Sep 2002 | B1 |
6455076 | Hahn et al. | Sep 2002 | B1 |
6468989 | Chang et al. | Oct 2002 | B1 |
6479058 | McCadden | Nov 2002 | B1 |
6486168 | Skwierczynski et al. | Nov 2002 | B1 |
6488947 | Bekele | Dec 2002 | B1 |
6511655 | Muller et al. | Jan 2003 | B1 |
6514487 | Barr | Feb 2003 | B1 |
6524594 | Santora et al. | Feb 2003 | B1 |
6531118 | Gonzalez et al. | Mar 2003 | B1 |
6534455 | Maurin et al. | Mar 2003 | B1 |
6536629 | van der Heijden | Mar 2003 | B2 |
6544530 | Friedman | Apr 2003 | B1 |
6544562 | Singh et al. | Apr 2003 | B2 |
6547063 | Zaveri et al. | Apr 2003 | B1 |
6548074 | Mohammadi | Apr 2003 | B1 |
6562355 | Renault | May 2003 | B1 |
6566350 | Ono et al. | May 2003 | B2 |
6582679 | Stein et al. | Jun 2003 | B2 |
6582710 | Deckers et al. | Jun 2003 | B2 |
6589509 | Keller et al. | Jul 2003 | B2 |
6596287 | Deckers et al. | Jul 2003 | B2 |
6599513 | Deckers et al. | Jul 2003 | B2 |
6620773 | Stork et al. | Sep 2003 | B1 |
6638981 | Williams et al. | Oct 2003 | B2 |
6649571 | Morgan | Nov 2003 | B1 |
6649574 | Cardis et al. | Nov 2003 | B2 |
6672483 | Roy | Jan 2004 | B1 |
6682726 | Marchesi et al. | Jan 2004 | B2 |
6691898 | Hurray et al. | Feb 2004 | B2 |
6709663 | Espinoza | Mar 2004 | B2 |
6723309 | Deane | Apr 2004 | B1 |
6730288 | Abram | May 2004 | B1 |
6753000 | Breton et al. | Jun 2004 | B2 |
6753167 | Moloney et al. | Jun 2004 | B2 |
6762158 | Lukenbach et al. | Jul 2004 | B2 |
6765001 | Gans et al. | Jul 2004 | B2 |
6774114 | Castiel et al. | Aug 2004 | B2 |
6777591 | Chaudhary et al. | Aug 2004 | B1 |
6790435 | Ma et al. | Sep 2004 | B1 |
6796973 | Contente et al. | Sep 2004 | B1 |
RE38623 | Hernandez et al. | Oct 2004 | E |
6811767 | Bosch et al. | Nov 2004 | B1 |
6834778 | Jinbo et al. | Dec 2004 | B2 |
6843390 | Bristor | Jan 2005 | B1 |
6875438 | Kraemer et al. | Apr 2005 | B2 |
6881271 | Ochiai | Apr 2005 | B2 |
6890567 | Nakatsu et al. | May 2005 | B2 |
6902737 | Quemin et al. | Jun 2005 | B2 |
6911211 | Eini et al. | Jun 2005 | B2 |
6946120 | Wai-Chiu So et al. | Sep 2005 | B2 |
6946139 | Henning | Sep 2005 | B2 |
6951654 | Malcolm et al. | Oct 2005 | B2 |
6955816 | Klysz | Oct 2005 | B2 |
6956062 | Beilfuss et al. | Oct 2005 | B2 |
6958154 | Andolino Brandt et al. | Oct 2005 | B2 |
6967023 | Eini et al. | Nov 2005 | B1 |
6968982 | Burns | Nov 2005 | B1 |
6969521 | Gonzalez et al. | Nov 2005 | B1 |
RE38964 | Shillington | Jan 2006 | E |
6994863 | Eini et al. | Feb 2006 | B2 |
7002486 | Lawrence | Feb 2006 | B2 |
7014844 | Mahalingam et al. | Mar 2006 | B2 |
7021499 | Hansen et al. | Apr 2006 | B2 |
7029659 | Abram | Apr 2006 | B2 |
7060253 | Mundschenk | Jun 2006 | B1 |
7078058 | Jones et al. | Jul 2006 | B2 |
7083799 | Giacomoni | Aug 2006 | B1 |
7137536 | Walters et al. | Nov 2006 | B2 |
7195135 | Garcia | Mar 2007 | B1 |
7222802 | Sweeton | May 2007 | B2 |
7225518 | Eidenschink et al. | Jun 2007 | B2 |
7226230 | Liberatore | Jun 2007 | B2 |
7235251 | Hamer et al. | Jun 2007 | B2 |
7270828 | Masuda et al. | Sep 2007 | B2 |
7455195 | Mekata | Nov 2008 | B2 |
7497354 | Decottignies et al. | Mar 2009 | B2 |
7575739 | Tamarkin et al. | Aug 2009 | B2 |
7645803 | Tamarkin et al. | Jan 2010 | B2 |
7654415 | van der Heijden | Feb 2010 | B2 |
7682623 | Eini et al. | Mar 2010 | B2 |
7700076 | Tamarkin et al. | Apr 2010 | B2 |
7704518 | Tamarkin et al. | Apr 2010 | B2 |
7793807 | Goujon et al. | Sep 2010 | B2 |
7820145 | Tamarkin et al. | Oct 2010 | B2 |
7960416 | Sato et al. | Jun 2011 | B2 |
8119106 | Tamarkin et al. | Feb 2012 | B2 |
20010006654 | Cannell et al. | Jul 2001 | A1 |
20010027218 | Stern et al. | Oct 2001 | A1 |
20010027981 | Yquel | Oct 2001 | A1 |
20010036450 | Verite et al. | Nov 2001 | A1 |
20020002151 | Ono et al. | Jan 2002 | A1 |
20020004063 | Zhang | Jan 2002 | A1 |
20020013481 | Schonrock et al. | Jan 2002 | A1 |
20020015721 | Simonnet et al. | Feb 2002 | A1 |
20020032171 | Chen et al. | Mar 2002 | A1 |
20020035046 | Lukenbach et al. | Mar 2002 | A1 |
20020035070 | Gardlik et al. | Mar 2002 | A1 |
20020035087 | Barclay | Mar 2002 | A1 |
20020035182 | L'Alloret et al. | Mar 2002 | A1 |
20020039591 | Dahle | Apr 2002 | A1 |
20020044659 | Ohta | Apr 2002 | A1 |
20020045659 | Michelet et al. | Apr 2002 | A1 |
20020048798 | Avery et al. | Apr 2002 | A1 |
20020058010 | Picard-Lesboueyries et al. | May 2002 | A1 |
20020072544 | Miller et al. | Jun 2002 | A1 |
20020090386 | Halswanter et al. | Jul 2002 | A1 |
20020098215 | Douin et al. | Jul 2002 | A1 |
20020111281 | Vishnupad | Aug 2002 | A1 |
20020117516 | Lasserre et al. | Aug 2002 | A1 |
20020134376 | Castro et al. | Sep 2002 | A1 |
20020136755 | Tyrrell et al. | Sep 2002 | A1 |
20020143188 | Garvey et al. | Oct 2002 | A1 |
20020153390 | Vlodek | Oct 2002 | A1 |
20020165170 | Wilson et al. | Nov 2002 | A1 |
20020182162 | Shahinpoor et al. | Dec 2002 | A1 |
20020187181 | Godbey et al. | Dec 2002 | A1 |
20020198136 | Mak et al. | Dec 2002 | A1 |
20030006193 | Ikeda et al. | Jan 2003 | A1 |
20030031693 | Breton et al. | Feb 2003 | A1 |
20030053961 | Eccard | Mar 2003 | A1 |
20030077297 | Chen et al. | Apr 2003 | A1 |
20030078172 | Guiramand et al. | Apr 2003 | A1 |
20030114520 | Pereira et al. | Jun 2003 | A1 |
20030118515 | Jew et al. | Jun 2003 | A1 |
20030130247 | Gans et al. | Jul 2003 | A1 |
20030175232 | Elliott et al. | Sep 2003 | A1 |
20030175315 | Yoo et al. | Sep 2003 | A1 |
20030180347 | Young et al. | Sep 2003 | A1 |
20030185839 | Podolsky | Oct 2003 | A1 |
20030194379 | Brugger et al. | Oct 2003 | A1 |
20030195128 | Deckman et al. | Oct 2003 | A1 |
20030206955 | Sonneville-Aubrun et al. | Nov 2003 | A1 |
20030215472 | Bonda et al. | Nov 2003 | A1 |
20040018228 | Fischell et al. | Jan 2004 | A1 |
20040028752 | Kamm et al. | Feb 2004 | A1 |
20040038912 | Michelet et al. | Feb 2004 | A1 |
20040053797 | Chen et al. | Mar 2004 | A1 |
20040058878 | Walker | Mar 2004 | A1 |
20040063787 | Villanueva | Apr 2004 | A1 |
20040067970 | Foster et al. | Apr 2004 | A1 |
20040072638 | Enos et al. | Apr 2004 | A1 |
20040076651 | Brocks et al. | Apr 2004 | A1 |
20040078896 | Hellyer et al. | Apr 2004 | A1 |
20040079361 | Clayton et al. | Apr 2004 | A1 |
20040105825 | Henning | Jun 2004 | A1 |
20040120917 | Perrier et al. | Jun 2004 | A1 |
20040127554 | Ghisalberti | Jul 2004 | A1 |
20040138179 | Goldstein et al. | Jul 2004 | A1 |
20040151671 | Abram et al. | Aug 2004 | A1 |
20040151756 | Richards et al. | Aug 2004 | A1 |
20040161447 | Paul | Aug 2004 | A1 |
20040184992 | Abram | Sep 2004 | A1 |
20040185123 | Mazzio et al. | Sep 2004 | A1 |
20040191196 | Tamarkin | Sep 2004 | A1 |
20040192754 | Shapira et al. | Sep 2004 | A1 |
20040195276 | Fuchs | Oct 2004 | A1 |
20040197276 | Takase et al. | Oct 2004 | A1 |
20040197295 | Riedel et al. | Oct 2004 | A1 |
20040219122 | Masuda et al. | Nov 2004 | A1 |
20040219176 | Dominguez | Nov 2004 | A1 |
20040220187 | Stephenson et al. | Nov 2004 | A1 |
20040229813 | DiPiano et al. | Nov 2004 | A1 |
20040234475 | Lannibois-Drean et al. | Nov 2004 | A1 |
20040241099 | Popp et al. | Dec 2004 | A1 |
20040247531 | Riedel et al. | Dec 2004 | A1 |
20040253275 | Eini et al. | Dec 2004 | A1 |
20040258627 | Riedel et al. | Dec 2004 | A1 |
20040265240 | Tamarkin et al. | Dec 2004 | A1 |
20050002976 | Wu | Jan 2005 | A1 |
20050013853 | Gil-Ad et al. | Jan 2005 | A1 |
20050031547 | Tamarkin et al. | Feb 2005 | A1 |
20050042182 | Arkin et al. | Feb 2005 | A1 |
20050054991 | Tobyn et al. | Mar 2005 | A1 |
20050069566 | Tamarkin et al. | Mar 2005 | A1 |
20050074414 | Tamarkin et al. | Apr 2005 | A1 |
20050075407 | Tamarkin et al. | Apr 2005 | A1 |
20050079139 | Jacques et al. | Apr 2005 | A1 |
20050084551 | Jensen et al. | Apr 2005 | A1 |
20050085843 | Opolski et al. | Apr 2005 | A1 |
20050101936 | Gonzales et al. | May 2005 | A1 |
20050106197 | Blin et al. | May 2005 | A1 |
20050123494 | Swaile et al. | Jun 2005 | A1 |
20050123496 | Shah et al. | Jun 2005 | A1 |
20050186142 | Tamarkin et al. | Aug 2005 | A1 |
20050186147 | Tamarkin et al. | Aug 2005 | A1 |
20050189377 | Lanzendorfer et al. | Sep 2005 | A1 |
20050196414 | Dake et al. | Sep 2005 | A1 |
20050205086 | Tamarkin et al. | Sep 2005 | A1 |
20050207837 | Kosh et al. | Sep 2005 | A1 |
20050222090 | Cheng et al. | Oct 2005 | A1 |
20050232869 | Tamarkin et al. | Oct 2005 | A1 |
20050244342 | Friedman et al. | Nov 2005 | A1 |
20050244354 | Speron | Nov 2005 | A1 |
20050245902 | Cornish et al. | Nov 2005 | A1 |
20050252995 | Westphal et al. | Nov 2005 | A1 |
20050255048 | Hirsh et al. | Nov 2005 | A1 |
20050258189 | Peterson et al. | Nov 2005 | A1 |
20050266035 | Healy et al. | Dec 2005 | A1 |
20050268416 | Sommers | Dec 2005 | A1 |
20050271596 | Friedman et al. | Dec 2005 | A1 |
20050271598 | Friedman et al. | Dec 2005 | A1 |
20050276836 | Wilson et al. | Dec 2005 | A1 |
20050281755 | Zarif et al. | Dec 2005 | A1 |
20050281766 | Martin et al. | Dec 2005 | A1 |
20050285912 | Delametter et al. | Dec 2005 | A1 |
20050287081 | Aust et al. | Dec 2005 | A1 |
20060008432 | Scarampi et al. | Jan 2006 | A1 |
20060018937 | Friedman et al. | Jan 2006 | A1 |
20060018938 | Neubourg | Jan 2006 | A1 |
20060029565 | Xu et al. | Feb 2006 | A1 |
20060051301 | Galopin et al. | Mar 2006 | A1 |
20060054634 | Mekata | Mar 2006 | A1 |
20060057168 | Larm et al. | Mar 2006 | A1 |
20060088561 | Eini et al. | Apr 2006 | A1 |
20060099151 | Neubourg | May 2006 | A1 |
20060108377 | Glynn et al. | May 2006 | A1 |
20060110418 | Johnson | May 2006 | A1 |
20060114745 | Ollmann et al. | Jun 2006 | A1 |
20060121073 | Goyal et al. | Jun 2006 | A1 |
20060140984 | Tamarkin et al. | Jun 2006 | A1 |
20060140990 | Bortz et al. | Jun 2006 | A1 |
20060160713 | Sekine et al. | Jul 2006 | A1 |
20060165616 | Brock et al. | Jul 2006 | A1 |
20060177392 | Walden | Aug 2006 | A1 |
20060193789 | Tamarkin et al. | Aug 2006 | A1 |
20060193813 | Simonnet | Aug 2006 | A1 |
20060204446 | Lulla et al. | Sep 2006 | A1 |
20060222675 | Sabnis et al. | Oct 2006 | A1 |
20060233721 | Tamarkin et al. | Oct 2006 | A1 |
20060239937 | Neubourg | Oct 2006 | A2 |
20060251684 | Annis et al. | Nov 2006 | A1 |
20060254597 | Thompson | Nov 2006 | A1 |
20060263323 | Hoang et al. | Nov 2006 | A1 |
20060269485 | Friedman et al. | Nov 2006 | A1 |
20060272199 | Licciardello et al. | Dec 2006 | A1 |
20060275218 | Tamarkin et al. | Dec 2006 | A1 |
20060275221 | Tamarkin et al. | Dec 2006 | A1 |
20060285912 | Eini et al. | Dec 2006 | A1 |
20060292080 | Abram et al. | Dec 2006 | A1 |
20070009607 | Jones | Jan 2007 | A1 |
20070017696 | Lin et al. | Jan 2007 | A1 |
20070020213 | Tamarkin et al. | Jan 2007 | A1 |
20070020304 | Tamarkin et al. | Jan 2007 | A1 |
20070027055 | Koivisto et al. | Feb 2007 | A1 |
20070036831 | Baker | Feb 2007 | A1 |
20070059253 | Popp et al. | Mar 2007 | A1 |
20070069046 | Eini et al. | Mar 2007 | A1 |
20070071688 | Illel et al. | Mar 2007 | A1 |
20070098647 | Neubourg | May 2007 | A1 |
20070134174 | Irwin et al. | Jun 2007 | A1 |
20070140999 | Puglia et al. | Jun 2007 | A1 |
20070142263 | Stahl et al. | Jun 2007 | A1 |
20070148112 | Dingley et al. | Jun 2007 | A1 |
20070148194 | Amiji et al. | Jun 2007 | A1 |
20070154402 | Trumbore et al. | Jul 2007 | A1 |
20070160548 | Riccardi et al. | Jul 2007 | A1 |
20070224143 | Konis | Sep 2007 | A1 |
20070237724 | Abram et al. | Oct 2007 | A1 |
20070253911 | Tamarkin et al. | Nov 2007 | A1 |
20070264317 | Yosha et al. | Nov 2007 | A1 |
20070271235 | Frank et al. | Nov 2007 | A1 |
20070280891 | Tamarkin et al. | Dec 2007 | A1 |
20070281999 | Fox et al. | Dec 2007 | A1 |
20070292355 | Tamarkin et al. | Dec 2007 | A1 |
20070292359 | Friedman et al. | Dec 2007 | A1 |
20070292461 | Tamarkin et al. | Dec 2007 | A1 |
20080008397 | Kisilev | Jan 2008 | A1 |
20080015263 | Bolotin et al. | Jan 2008 | A1 |
20080015271 | Abram et al. | Jan 2008 | A1 |
20080031907 | Tamarkin et al. | Feb 2008 | A1 |
20080031908 | Aubrun-Sonneville et al. | Feb 2008 | A1 |
20080035155 | Dahl | Feb 2008 | A1 |
20080044444 | Tamarkin et al. | Feb 2008 | A1 |
20080058055 | LeMay et al. | Mar 2008 | A1 |
20080063682 | Cashman et al. | Mar 2008 | A1 |
20080069779 | Tamarkin et al. | Mar 2008 | A1 |
20080131378 | Keller et al. | Jun 2008 | A1 |
20080138293 | Tamarkin et al. | Jun 2008 | A1 |
20080138296 | Tamarkin et al. | Jun 2008 | A1 |
20080152596 | Friedman et al. | Jun 2008 | A1 |
20080153789 | Dmowski et al. | Jun 2008 | A1 |
20080166303 | Tamarkin et al. | Jul 2008 | A1 |
20080167376 | Bar-Or et al. | Jul 2008 | A1 |
20080181854 | Eini et al. | Jul 2008 | A1 |
20080188445 | Muldoon et al. | Aug 2008 | A1 |
20080188446 | Muldoon et al. | Aug 2008 | A1 |
20080193762 | Dubertret et al. | Aug 2008 | A1 |
20080206155 | Tamarkin et al. | Aug 2008 | A1 |
20080206159 | Tamarkin et al. | Aug 2008 | A1 |
20080206161 | Tamarkin et al. | Aug 2008 | A1 |
20080241079 | Neubourg | Oct 2008 | A1 |
20080253973 | Tamarkin et al. | Oct 2008 | A1 |
20080255498 | Houle | Oct 2008 | A1 |
20080260655 | Tamarkin et al. | Oct 2008 | A1 |
20080292560 | Tamarkin et al. | Nov 2008 | A1 |
20080299220 | Tamarkin et al. | Dec 2008 | A1 |
20080311167 | Oronsky et al. | Dec 2008 | A1 |
20080317679 | Tamarkin et al. | Dec 2008 | A1 |
20090041680 | Tamarkin et al. | Feb 2009 | A1 |
20090068118 | Eini et al. | Mar 2009 | A1 |
20090093514 | Statham et al. | Apr 2009 | A1 |
20090130029 | Tamarkin et al. | May 2009 | A1 |
20090131488 | Harel et al. | May 2009 | A1 |
20090175799 | Tamarkin et al. | Jul 2009 | A1 |
20090180970 | Tamarkin et al. | Jul 2009 | A1 |
20090291917 | Akama et al. | Nov 2009 | A1 |
20100111879 | Tamarkin et al. | May 2010 | A1 |
20100221194 | Loupenok | Sep 2010 | A1 |
20100266510 | Tamarkin et al. | Oct 2010 | A1 |
20110002857 | Tamarkin et al. | Jan 2011 | A1 |
20110002969 | Serraima et al. | Jan 2011 | A1 |
20110212033 | Tamarkin et al. | Sep 2011 | A1 |
20110268665 | Tamarkin et al. | Nov 2011 | A1 |
Number | Date | Country |
---|---|---|
198780257 | Sep 1986 | AU |
2422244 | Sep 2003 | CA |
639913 | Dec 1983 | CH |
1 882 100 | Nov 1963 | DE |
1926796 | Nov 1965 | DE |
4140474 | Jun 1993 | DE |
10009233 | Aug 2000 | DE |
10138495 | Feb 2003 | DE |
102004016710 | Oct 2005 | DE |
2 608 226 | Sep 2007 | DE |
0 156 507 | Oct 1985 | EP |
0 186 453 | Jul 1986 | EP |
0 211 550 | Feb 1987 | EP |
0 214 865 | Mar 1987 | EP |
0 216 856 | Apr 1987 | EP |
0 270 316 | Jun 1988 | EP |
0 297 436 | Jan 1989 | EP |
0 326 196 | Aug 1989 | EP |
0 336 812 | Oct 1989 | EP |
0 391 124 | Oct 1990 | EP |
0 404 376 | Dec 1990 | EP |
0 414 920 | Mar 1991 | EP |
0 484 530 | May 1992 | EP |
0 485 299 | May 1992 | EP |
0 488 089 | Jun 1992 | EP |
0 504 301 | Sep 1992 | EP |
0 528 190 | Feb 1993 | EP |
0 535 327 | Apr 1993 | EP |
0 552 612 | Jul 1993 | EP |
0 569 773 | Nov 1993 | EP |
0 598 412 | May 1994 | EP |
0 662 431 | Jul 1995 | EP |
0 676 198 | Oct 1995 | EP |
0 738 516 | Oct 1996 | EP |
0 757 959 | Feb 1997 | EP |
0 824 911 | Feb 1998 | EP |
0 829 259 | Mar 1998 | EP |
0 928 608 | Jul 1999 | EP |
0 979 654 | Feb 2000 | EP |
0 993 827 | Apr 2000 | EP |
1 025 836 | Aug 2000 | EP |
1 055 425 | Nov 2000 | EP |
0 506 197 | Jul 2001 | EP |
1 215 258 | Jun 2002 | EP |
1 287 813 | Mar 2003 | EP |
1 308 169 | May 2003 | EP |
1 375 386 | Jan 2004 | EP |
1 428 521 | Jun 2004 | EP |
1 438 946 | Jul 2004 | EP |
1 189 579 | Sep 2004 | EP |
1 475 381 | Nov 2004 | EP |
1 483 001 | Dec 2004 | EP |
1 500 385 | Jan 2005 | EP |
1 537 916 | Jun 2005 | EP |
1 600 185 | Nov 2005 | EP |
1 734 927 | Dec 2006 | EP |
1 758 547 | Mar 2007 | EP |
1 584 324 | Nov 2007 | EP |
1 889 609 | Feb 2008 | EP |
2 591 331 | Jun 1987 | FR |
2 640 942 | Jun 1990 | FR |
2 736 824 | Jan 1997 | FR |
2 774 595 | Aug 1999 | FR |
2 789 371 | Aug 2000 | FR |
2 793 479 | Nov 2000 | FR |
2 814 959 | Apr 2002 | FR |
2 833 246 | Jun 2003 | FR |
2 840 903 | Dec 2003 | FR |
2 843 373 | Feb 2004 | FR |
2 845 672 | Apr 2004 | FR |
2 848 998 | Jun 2004 | FR |
2 860 976 | Apr 2005 | FR |
2 915 891 | Nov 2008 | FR |
808 104 | Jan 1959 | GB |
808 105 | Jan 1959 | GB |
922 930 | Apr 1963 | GB |
933 486 | Aug 1963 | GB |
998 490 | Jul 1965 | GB |
1 026 831 | Apr 1966 | GB |
1 033 299 | Jun 1966 | GB |
1 081 949 | Sep 1967 | GB |
1 121 358 | Jul 1968 | GB |
1 162 684 | Aug 1969 | GB |
1 170 152 | Nov 1969 | GB |
1 201 918 | Aug 1970 | GB |
1 347 950 | Feb 1974 | GB |
1 351 761 | May 1974 | GB |
1 351 762 | May 1974 | GB |
1 353 381 | May 1974 | GB |
1 376 649 | Dec 1974 | GB |
1 397 285 | Jun 1975 | GB |
1 408 036 | Oct 1975 | GB |
1 457 671 | Dec 1976 | GB |
1 489 672 | Oct 1977 | GB |
2 004 746 | Apr 1979 | GB |
1 561 423 | Feb 1980 | GB |
2 114 580 | Aug 1983 | GB |
2 153 686 | Aug 1985 | GB |
2 172 298 | Sep 1986 | GB |
2 206 099 | Dec 1988 | GB |
2 166 651 | May 1996 | GB |
2 337 461 | Nov 1999 | GB |
2 367 809 | Apr 2002 | GB |
2 406 330 | Mar 2005 | GB |
2 406 791 | Apr 2005 | GB |
49491 | Sep 1979 | IL |
152 486 | May 2003 | IL |
60001113 | Apr 1978 | JP |
55069682 | May 1980 | JP |
57044429 | Mar 1982 | JP |
56039815 | Apr 1984 | JP |
61275395 | Dec 1986 | JP |
62241701 | Oct 1987 | JP |
63119420 | May 1988 | JP |
1100111 | Apr 1989 | JP |
1156906 | Jun 1989 | JP |
2184614 | Jul 1990 | JP |
2255890 | Oct 1990 | JP |
4282311 | Oct 1992 | JP |
4312521 | Nov 1992 | JP |
5070340 | Mar 1993 | JP |
5213734 | Aug 1993 | JP |
6100414 | Apr 1994 | JP |
H06-263630 | Jun 1994 | JP |
6329532 | Nov 1994 | JP |
2007155667 | Jun 1995 | JP |
7215835 | Aug 1995 | JP |
2008040899 | Feb 1996 | JP |
8501529 | Feb 1996 | JP |
8119831 | May 1996 | JP |
8165218 | Jun 1996 | JP |
8277209 | Oct 1996 | JP |
09 084855 | Mar 1997 | JP |
9099553 | Apr 1997 | JP |
9110636 | Apr 1997 | JP |
10114619 | May 1998 | JP |
3050289 | Sep 1998 | JP |
2010332456 | Dec 1998 | JP |
11501045 | Jan 1999 | JP |
11250543 | Sep 1999 | JP |
2000017174 | Jan 2000 | JP |
2000080017 | Mar 2000 | JP |
2000128734 | May 2000 | JP |
2000191429 | Jul 2000 | JP |
2000239140 | Sep 2000 | JP |
2000351726 | Dec 2000 | JP |
2000354623 | Dec 2000 | JP |
2001002526 | Jan 2001 | JP |
2001019606 | Jan 2001 | JP |
2001072963 | Mar 2001 | JP |
2002012513 | Jan 2002 | JP |
2002047136 | Feb 2002 | JP |
2002524490 | Aug 2002 | JP |
2002302419 | Oct 2002 | JP |
2003012511 | Jan 2003 | JP |
2003055146 | Feb 2003 | JP |
2004047136 | Feb 2004 | JP |
2004250435 | Sep 2004 | JP |
2004348277 | Dec 2004 | JP |
2005314323 | Nov 2005 | JP |
2005350378 | Dec 2005 | JP |
2006008574 | Jan 2006 | JP |
2006036317 | Feb 2006 | JP |
2006103799 | Apr 2006 | JP |
2006525145 | Nov 2006 | JP |
2007131539 | May 2007 | JP |
2007326996 | Dec 2007 | JP |
143232 | Jul 1998 | KR |
2001003063 | Jan 2001 | KR |
2277501 | Jun 2006 | RU |
66796 | Jun 2004 | UA |
8201821 | Jun 1982 | WO |
8605389 | Sep 1986 | WO |
8801502 | Mar 1988 | WO |
8801863 | Mar 1988 | WO |
8808316 | Nov 1988 | WO |
8906537 | Jul 1989 | WO |
9005774 | May 1990 | WO |
9111991 | Aug 1991 | WO |
9200077 | Jan 1992 | WO |
9205142 | Apr 1992 | WO |
9205763 | Apr 1992 | WO |
9211839 | Jul 1992 | WO |
9325189 | Dec 1993 | WO |
9406440 | Mar 1994 | WO |
9603115 | Feb 1996 | WO |
9619921 | Jul 1996 | WO |
9624325 | Aug 1996 | WO |
9626711 | Sep 1996 | WO |
9627376 | Sep 1996 | WO |
9639119 | Dec 1996 | WO |
9703638 | Feb 1997 | WO |
9739745 | Oct 1997 | WO |
9817282 | Apr 1998 | WO |
9818472 | May 1998 | WO |
9819654 | May 1998 | WO |
9821955 | May 1998 | WO |
9823291 | Jun 1998 | WO |
9836733 | Aug 1998 | WO |
9852536 | Nov 1998 | WO |
9908649 | Feb 1999 | WO |
9920250 | Apr 1999 | WO |
9937282 | Jul 1999 | WO |
9953923 | Oct 1999 | WO |
0009082 | Feb 2000 | WO |
0015193 | Mar 2000 | WO |
0023051 | Apr 2000 | WO |
0033825 | Jun 2000 | WO |
0038731 | Jul 2000 | WO |
0061076 | Oct 2000 | WO |
0076461 | Dec 2000 | WO |
0105366 | Jan 2001 | WO |
0108681 | Feb 2001 | WO |
0110961 | Feb 2001 | WO |
0153198 | Jul 2001 | WO |
0154212 | Jul 2001 | WO |
0154679 | Aug 2001 | WO |
0162209 | Aug 2001 | WO |
0170242 | Sep 2001 | WO |
0182880 | Nov 2001 | WO |
0182890 | Nov 2001 | WO |
0185102 | Nov 2001 | WO |
0185128 | Nov 2001 | WO |
0195728 | Dec 2001 | WO |
0200820 | Jan 2002 | WO |
0215860 | Feb 2002 | WO |
0215873 | Feb 2002 | WO |
0228435 | Apr 2002 | WO |
0241847 | May 2002 | WO |
0243490 | Jun 2002 | WO |
02062324 | Aug 2002 | WO |
02078667 | Oct 2002 | WO |
02087519 | Nov 2002 | WO |
03000223 | Jan 2003 | WO |
03002082 | Jan 2003 | WO |
03013984 | Feb 2003 | WO |
03051294 | Jun 2003 | WO |
03053292 | Jul 2003 | WO |
03055445 | Jul 2003 | WO |
03055454 | Jul 2003 | WO |
03070301 | Aug 2003 | WO |
03071995 | Sep 2003 | WO |
03075851 | Sep 2003 | WO |
03092641 | Nov 2003 | WO |
03097002 | Nov 2003 | WO |
2004017962 | Mar 2004 | WO |
2004037197 | May 2004 | WO |
2004037225 | May 2004 | WO |
2004003284 | Aug 2004 | WO |
2004064769 | Aug 2004 | WO |
2004064833 | Aug 2004 | WO |
2004071479 | Aug 2004 | WO |
2004078158 | Sep 2004 | WO |
2004078896 | Sep 2004 | WO |
2004093895 | Nov 2004 | WO |
2004112780 | Dec 2004 | WO |
2005011567 | Feb 2005 | WO |
2005018530 | Mar 2005 | WO |
2005032522 | Apr 2005 | WO |
2005044219 | May 2005 | WO |
2005063224 | Jul 2005 | WO |
2005065652 | Jul 2005 | WO |
2005076697 | Aug 2005 | WO |
2005097068 | Oct 2005 | WO |
2005102282 | Nov 2005 | WO |
2005102539 | Nov 2005 | WO |
2005117813 | Dec 2005 | WO |
2006003481 | Jan 2006 | WO |
2006010589 | Feb 2006 | WO |
2006011046 | Feb 2006 | WO |
2006020682 | Feb 2006 | WO |
2006028339 | Mar 2006 | WO |
2006031271 | Mar 2006 | WO |
2006045170 | May 2006 | WO |
2006079632 | Aug 2006 | WO |
2006081327 | Aug 2006 | WO |
2006091229 | Aug 2006 | WO |
2006100485 | Sep 2006 | WO |
2006120682 | Nov 2006 | WO |
2006121610 | Nov 2006 | WO |
2006122158 | Nov 2006 | WO |
2006129161 | Dec 2006 | WO |
2006131784 | Dec 2006 | WO |
2007007208 | Jan 2007 | WO |
2007012977 | Feb 2007 | WO |
2007023396 | Mar 2007 | WO |
2007031621 | Mar 2007 | WO |
2007039825 | Apr 2007 | WO |
2007050543 | May 2007 | WO |
2007054818 | May 2007 | WO |
2007072216 | Jun 2007 | WO |
2007085899 | Aug 2007 | WO |
2007085902 | Aug 2007 | WO |
2007099396 | Sep 2007 | WO |
2007111962 | Oct 2007 | WO |
2008008397 | Jan 2008 | WO |
2008010963 | Jan 2008 | WO |
2008038147 | Apr 2008 | WO |
2008041045 | Apr 2008 | WO |
2008075207 | Jun 2008 | WO |
2008087148 | Jul 2008 | WO |
2008110872 | Sep 2008 | WO |
2008152444 | Dec 2008 | WO |
2009007785 | Jan 2009 | WO |
2009069006 | Jun 2009 | WO |
2009072007 | Jun 2009 | WO |
2009087578 | Jul 2009 | WO |
2009090495 | Jul 2009 | WO |
2009090558 | Jul 2009 | WO |
2009098595 | Aug 2009 | WO |
2011039637 | Apr 2011 | WO |
2011039638 | Apr 2011 | WO |
Entry |
---|
U.S. Appl. No. 60/789,186, filed Apr. 4, 2006, Tamarkin. |
U.S. Appl. No. 60/815,948, filed Jun. 23, 2006, Tamarkin. |
U.S. Appl. No. 60/818,634, filed Jul. 5, 2006, Friedman. |
U.S. Appl. No. 60/843,140, filed Sep. 8, 2006, Tamarkin. |
U.S. Appl. No. 61/248,144, filed Oct. 2, 2009, Tamarkin. |
U.S. Appl. No. 61/322,148, filed Apr. 8, 2010, Tamarkin. |
U.S. Appl. No. 61/363,577, filed Jul. 12, 2010, Eini. |
“HLB Systems”, http://pharmcal.tripod.com/ch17.htm, Accessed Sep. 17, 2010, pp. 1-3. |
‘Surfactant’ [online]. Wikipedia, 2010, [retrieved on Oct. 24, 2010]. Retrieved from the Internet: <URL: http://en.wikipedia.org/wiki/Surfactant>, 7 pages. |
Adachi, Shuji. “Storage and Oxidative Stability of O/W/ Nano-emulsions.” Foods Food Ingredients. J. Jpn. vol. 209, No. 11. 2004. 1 page. |
Alcohol SDA 40B.http://www.pharmco-prod.com/pages/MSDS/SDA.sub.--40B.sub.--200.pdf Accessed Dec. 9, 2008, 2 pages. |
Ambrose, Ursula et al., “In Vitro Studies of Water Activity and Bacterial Growth Inhibition of Sucrose-Polyethylene Glycol 400-Hydrogen Peroxide and Xylose-Polyethylene Glycol 400-Hydrogen Peroxide Pastes Used to Treat Infected Wounds,” Antimicrobial Agents and Chemotherapy, vol. 35, No. 9, pp. 1799-1803, 1991. |
Anton, N. et al. “Water-in-Oil Nano-Emulsion Formation by the phase inversion Temperature Method: A Novel and General Concept, a New Template for Nanoencapsulation,” Proceedings of the 33rd Annual Meeting and Exposition of the Controlled Release Society, Jul. 2006, Vienna, Austria, 2 pages. |
Arct et al., “Common Cosmetic Hydrophilic Ingredients as Penetration Modifiers of Flavonoids”, International Journal of Cosmetic Science, 24(6):357-366 (2002)—Abstract, 1 page. |
Arisan, http://www.arisankimya.com/kozmetik.htm Accessed Dec. 10, 2008, 8 pages. |
Augsburger, Larry L. et al. “Bubble Size Analysis of High Consistency Aerosol Foams and Its Relationship to Foam Rheology. Effects of Container Emptying, Propellent Type, and Time.” Journal of Pharmaceutical Sciences. vol. 57, No. 4. Apr. 1968. pp. 624-631. |
Austria, et al., “Stability of Vitamin C Derivatives in Solution and Topical Formulations”, Journal of Pharmaceutical and Biomedical Analysis, 15:795-801 (1997). |
Barry, B.W. et al, Comparative bio-availability and activity of proprietary topical corticosteroid preparations: vasoconstrictor assays on thirty-one ointments, British Journal of Dermatology, 93, 563-571, 1975. |
Benet, et al., Application of NMR for the Determination of HLB Values of Nonionic Surfactants, Journal of the American Oil Chemists Society, vol. 49, 1972, 499-500. |
Bernstein, et al., Effects of the Immunomodulating Agent R837 on Acute and Latent Herpes Simplex Virus Type 2 Invections, Antimicrobial Agents and Chemotherapy, 33(9):1511-1515 (1989). |
Blute, “Phase behavior of alkyl glycerol ether surfacants”, Physical Chemistry Tenside Sur. Det., 35(3):207-212 (1998). |
Brenes, et al., “Stability of Copigmented Anthocyanins and Asorbics Acid in a Grape Juice Model System”, J. Agric Food Chem, 53(1):49-56 (2005)—Abstrace, 1 page. |
Bronopol. Revtrieved online on Jun. 4, 2011. <URL:http://chemicalland21.com/specialtychem/perchem/BRONOPOL.html>. Jul. 17, 2006. 4 pages. |
Buck, et al., “Treatment of Vaginal Intraephithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream”, Journal of Lower Genetial Tract Disease, 7(3):290-293 (2003). |
Bucks, Daniel A.W., et al., “Bioavailability of Topically Administered Steroids: A ‘Mass Balance’ Technique,” Journal of Investigative Dermatology, vol. 91, No. 1, Jul. 1988, pp. 29-33. |
Bunker,et al., “Alterations in Scalp Blood Flow after the Epicutaneous Application of 3% Minoxidil and 0.1% Hexyl Nicotinate in Alopecia”, Presented as a poster at the meeting of the British Society for Investigavie Dermatology, York, Sep. 1986 (2 pages). |
Burton, et al., “Hypertrichosis Due to Minoxidil”, British Journal of Dermatology, 101:593-595 (1979). |
Campos, et al., “Ascorbic Acid and Its Derivatives in Cosmetic Formulations”, Cosmetics and Toiletries, 115(6):59-62 (2000)—Abstract, 1 page. |
Carbowax 1000MSDS; http://www.sciencelab.com/xMSDS-Polyethylene.sub.--glycol.sub.--1000-9926-622. Accessed Dec. 13, 2008, 6 pages. |
Carelli, et al., “Effect of Vehicles on Yohimbine Permeation Across Excised Hairless Mouse Skin”, Pharm Acta Helv, 73(3):127-134 (1998)—Abstract, 1 page. |
Chebil, et al., “Soulbility of Flavonoids in Organic Solvents”, J. Chem. Eng. Data, 52(5):1552-1556 (2007)—Abstract, 1 page. |
Chevrant-Breton, et al., “Etude du Traitement Capillaire <<Bioscalin>> dans les Alopecies Diffuses de la Femme”, Gazette Medicale, 93(17):75-79 (1986) [English abstract]. |
Chiang, et al., “Bioavailability Assessment of Topical Delivery Systems: In Vitro Delivery of Minoxidil from Prototypical Semi-Solid Formulations”, Int. J. Pharm, 49(2):109-114 (1989)—Abstract, 1 page. |
Chinnian, et al., “Photostability Profiles of Minoxidil Solutions”, PDA J. Pharm Sci Technol., 50(2):94-98 (1996)—Abstract, 1 page. |
Chollet, et al., “Development of a Topically Active Imiquimod Formulation”, Pharmaceutical Development and Technology, 4(1):35-43 (1999). |
Chollet, et al., “The Effect of Temperatures on the Solubility of Immiquimod in Isostearic Acid”, Abstract 3031, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
Coetzee, “Acceptability and Feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides,” Nicol.AIDS 2001, vol. 15, No. 14, pp. 1837-1842. |
Colloidal Silica. Retrieved online on Jun. 4, 2011. <URL:http://www.grace.com/engineeredmaterials/materialsciences/colloidalsilica/default.aspx>. Copyright 2011. 4 pages. |
Croda 2. Croda Cetomacrogol 1000 Product Information Sheet. 2011 (no month given). 1 page. |
Croda. Aracel 165 Product Summary. 2011 (no month given). 1 page. |
D.W.A. Sharp Dictionary of Chemistry, Penguin Books, 1983, 3 pages. |
Dalby, “Determination of Drug Solubility in Aerosol Propellants,” Pharmaceutical Research, vol. 8, No. 9, 1991, pp. 1206-1209. |
Dawber, et al., “Hypertrichosis in Females Applying Minoxidil Topical Solution and in Normal Controls”, JEADV, 17:271-275 (2003). |
Denatonium Benzoate http://www.newdruginfo.com/pharmaceopeia/usp28/v28230/usp28nf23s0.sub.--m- 22790.htm Accessed Dec. 9, 2008, 2 pages. |
Dentinger, et al., “Stability of Nifedipine in an Extemporaneously Compounded Oral Solution”, American Journal of Health-System Pharmacy, 60(10):1019-1022 (2003)—Abstract, 1 page. |
Draelos, Z. D. “Antiperspirants and the Hyperhidrosis Patients.” Dermatologic Therapy. 2001. vol. 14. pp. 220-224. |
Edens, et al., “Storage Stability and Safey of Active Vitamin C in a New Dual-Chamber Dispenser”, Journal of Applied Cosmetology, 17(4):136-143 (1999)—Abstract, 1 page. |
Edirisinghe, et al., “Effect of fatty acids on endothelium-dependent relaxation in the rabbit aorta”, Clin Sci (Load). Aug. 2006; 111(2): 145-51. |
Edwards, “Imiquimod in Clinical Practice”, J. Am Acad Dermatol., 43(1, Pt 2):S12-S17 (2000)—Abstract, 1 page. |
Emulsifiers with HLB values. http://www.theherbarie.com/files/resources-center/formulating/Emulsifiers-.sub.--HLB.sub.--Values.pdf accessed Aug. 5, 2009 (3 pps). |
Encyclopedia of Pharmaceutical Technology, Second Edition, vol. 3, Copyright 2002, 4 pages. |
Esposito, E. et al. “Nanosystems for Skin Hydration: A Comparative Study.” International Journal of Cosmetic Science. 29. 2007. pp. 39-47. |
Ethanol, Accessed http://www.sigmaaldrich.com/catalog/ProductDetail.do?N4=E7023SIAL&N5=SEAR- CH.sub.--CONCAT.sub.--PNOBBRAND.sub.--KEY&F=SPEC Dec. 9, 2008, 2 pages. |
Ethylene Oxide Derivatives: An Essence of Every Industry. A definition of Emulsifier. Http://www.emulsifiers.in/ethylene—oxide—derivatives2.htm. Accessed Jul. 12, 2011. 3 pages. |
Farahmand, et al., “Formulation and Evaluation of a Vitamin C Multiple Emulsion”, Pharmaceutical Development and Technology, 11(2):255-261 (2006)—Abstract, 1 page. |
Final Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., Dec. 16, 2008, 24 pages. |
Flick, Cosmetic and Toiletry Formulations, vol. 5, 2nd Edition, Copyright 1996, 63 pages. Relevant pp. 251-309. |
Fontana, Anthony J., “Water Activity: Why It is Important for Food Safety,” International Conference on Food Safety, Nov. 16-18, 1998, pp. 177-185. |
Gallarate, et al., “On the Stability of Ascorbic Acid in Emulsified Systems for Topical and Cosmetic Use”, International Journal of Pharmaceutics, 188:233-241 (1999). |
Galligan, John et al., “Adhesive Polyurethane Liners for Anterior Restorations,” J. Dent. Res., Jul.-Aug. 1968, pp. 629-632. |
Gelbard et al. “Primary Pediatric Hyperhidrosis: A Review of Current Treatment Options.” Pediatric Dermatology. 2008. 25 (6). pp. 591-598. |
Graves, S. et al. “Structure of Concentrated Nanoemulsions.” The Journal of Chemical Physics.. 122 America Institute of Physics. Published Apr. 1, 2005. 6 pages. |
Hall, Karla, “Diaper Area Hemangiomas: A Unique Set of Concerns,” http://members.tripod.com/.about.Michelle.sub.--G/diaper.html, Dec. 1, 2008, 8 pages. |
Hallstar. Retrieved online on Jun. 4, 2011. <URL:http://www.hallstar.com/pis.php?product=1H022>. 1 page. |
Harrison, et al., “Effects of cytokines and R-837, a cytokine inducer, on UV-irradiation augmented recurrent genital herpes in guinea pigs”, Antivial Res., 15(4):315-322 (1991). |
Harrison, et al., “Modification of Immunological Responses and Clinical Disease During Topical R-837 Treatment of Genital HSV-2 Infection”, Antiviral Research, 10:209-224 (1988). |
Harrison, et al., “Pharmacokinetics and Safety of Iminquimod 5% Cream in the Treatment of Actinic Keratoses of the Face, Scalp, or Hands and Arms”, Arch. Dermatol. Res., 296(1):6-11 (2004)—Abstract, 1 page. |
Hashim, et al. “Tinea versicolor and visceral leishmaniasis,” Int J Dermatol., Apr. 1994; 33(4), pp. 258-259 (abstract only). |
Heart Failure, The Merck Manual, 2008 <<http://www.merck.com/mmhe/sec03/ch025/ch025a.html>> 12 pages. |
Hepburn, NC., “Cutaneous leishmaniasis,” Clin Exp Dermatol, Jul. 2000; 25(5), pp. 363-370 (abstract only). |
Hill, Randall M. (Ed.) Silicone Surfactants, Table of Contents and Chapter 7, “Silicone Surfactants: Applicants in the Personal Care Industry,” by David T. Floyd, 1999 (30 Pages). |
http://ibabydoc.com/online/diseaseeczema.asp., Atopic Dermatitis, Copyright 2000, 6 pages. |
http://web.archive.org/web/20000106225413/http://pharmacy.wilkes.edu/kibbeweb/lab7.html, Characteristics of Surfactants and Emulsions, Jan. 29, 2010, 5 pages. |
http://www.agworkshop.com/p3.asp, AG&Co. Essential oil workshop. 1 page. Accessed Jan. 31, 2010. |
Hubbe, Martin. Mini-Encyclopedia of Papermaking Wet-End Chemistry: Additives and Ingredients, their Composition, Functions, Strategies for Use. Retrieved online on Jun. 4, 2011. <URL://http://www4.ncsu.edu/˜hubbe/CSIL.htm>. Feb. 1, 2001. 2 pages. |
ICI Americas Inc. “The HLB System: A Time-Saving Guide to Emulsifier Selection.” Mar. 1980. pp. 1-22. |
Ikuta, et al., “Scanning Electron Microscopic Observation of Oil/Wax/Water/Surfacant System”, Journal of SCCJ, 34(4):280-291 (2004)—Abstract, 1 page. |
Indomethacin. Retrieved online on Jun. 3, 2011. <URL:http://it03.net/com/oxymatrine/down/1249534834.pdf>. Aug. 15, 2009. 3 pages. |
Innocenzi, Daniele et al., “An Open-Label Tolerability and Effacy Study of an Aluminum Sesquichlorhydrate Topical Foam in Axillary and Palmar Primary Hyperhidrosis,” Dermatologic Therapy, vol. 21, S27-S30, 2008. |
Izquierdo, P. et al. “Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method.” University of Barcelona. Sep. 17, 2001. 1 page. |
Kalkan, et al., The Measurement of Sweat Intensity Using a New Technique, Tr. J. of Medical Sciences 28, 515-517 (1998). |
Kanamoto, et al., “Pharmacokinetics of two rectal dosage forms of ketoprofen in patients after anal surgery,” J Pharmacobiodyn., Mar. 1988; 11(3):141-5. |
Kang,et al., “Enhancement of the Stability and Skin Penetration of Vitamin C by Polyphenol”, Immune Netw., 4(4):250-254 (2004)—Abstract, 1 page. |
Kathon.TM. CG (product information sheet by Rohm and Haas, Jun. 2006). |
Kim, “Stability of Minoxidil in Aqueous Solution”, Yakhak Hoechi, 30(5):228-231 (1986)—Abstract, 1 page. |
Kinnunen, “Skin reactions to hexylene glycol,” Contact Dermatitis Sep. 1989; 21(3): 154-8. |
Kleber, M.D., H.D. et al., “Treatment of Patients with Substance Use Disorders, Second Edition,” pp. 1-276, 2006. |
Kreuter, J. “Nanoparticles and microparticles for drug and vaccine delivery,” J. Anat. (1996) 189, pp. 503-505. |
Kumar, J. et ak., “Application of Broad Spectrum Antiseptic Povidone Iodine as Powerful Action: A Review,” Journal of Pharmaceutical Science and Technology vol. 1(2), 2009, 48-58. |
Kwak et al. “Study of Complete Transparent Nano-Emulsions which Contain Oils.” IFSCC Conference 2003, Seoul, Korea, Sep. 22-24, 2003. 3 pages. |
Lautenschlager, Dr. Hans. “A Closer Look on Natural Agents: Facts and Future Aspects.” Kosmetic Konzept. Kosmetische Praxis. 2006 (no month given). (5), 8-10. 3 pages. |
Lebwohl et al. “Treatment of Psoriasis. Part 1. Topical Therapy and Phototherapy.” J. Am. Acad. Dermatol. 45:487-498. Oct. 2001. |
Lee, et al., “The Stabilization of L-Ascorbic Acid in Aqueous Solution and Water-in-Oil-in-Water Double Emulsion by Controlling pH and Electrolyte Concentration”, J. Cosmet. Sci., 55:1-12 (Jan./Feb. 2004). |
Leung, et al., “Bioadhesive Drug Delivery in Water-Soluble Polymers,” American Chemical Society, Chapter 23, 1991, pp. 350-366. |
Licking Vaginal Dryness without a Prescription. Accessed http://www.estronaut.com/a/vag.sub.--dryness.htm on Dec. 14, 2008, 3 pages. |
Lippacher, A. et al. “Liquid and Semisolid SLN Dispersions for Topical Application” Rheological Characterization. European Journal of Pharmaceutics and Biopharmaceutics. 58. 2004. pp. 561-567. |
Lupo, “Antioxidants and Vitamins in Cosmetics”, Clinics in Dermatology, 19:467-473 (2001). |
Martindale, The extra pharmacopoeia [28th] edition, Eds.: Reynolds, J.E.F. and Prasad, A.B., The Pharmaceutical Press, London, pp. 862-864, 1982. |
Material Safety Data Sheet, Science Lab.com, Polyethylene Glycol 1000, MSDS, Nov. 6, 2008, 6 pages. |
Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition. O'Neil et al eds. Entries 1058, 2350, 6143, and 8803. 2001. 7 pages. |
Merck Manual Home Edition. “Excessive Sweating: Sweating Disorders.” Accessed Apr. 14, 2011 at www.merckmanuals.com/home/print/sec18/ch206/ch206c.html. 2 pages. |
Messenger, et al., “Minoxidil: Mechanisms of Action on Hair Growth”, British Journal of Dermatology, 150:186-194 (2004). |
Metz, et al., “A Phase I Study of Topical Tempol for the Prevention of Alopecia Induced by Whole Brain Radiotherapy”, Clinical Cancer Research, 10:6411-6417 (2004). |
Meucci, et al., “Ascorbic Acid Stability in Aqueous Solutions”, Acta Vitaminol Enzymol, 7(3-4):147-153 (1985)—Abstract, 1 page. |
MMP Inc. International Development and Manufacturing, “Formulating specialities,” http://mmpinc.com, 3 pages. Feb. 2, 2010. |
Molan, Peter Clark, “World Wide Wounds,” Dec. 2001, 13 pages. |
Morgan, Timothy M., et al., “Enhanced Skin Permeation of Sex Hormones with Novel Topical Spray Vehicles,” Journal of Pharmaceutical Sciences, vol. 87, No. 10, Oct. 1998, pp. 1213-1218. |
No Author Listed. “Opitmization of Nano-Emulsions Production by Microfluidization.” European Food Research and Technology. vol. 225, No. 5-6. Sep. 2007. Abstract. 1 page. |
Office Action for U.S. Appl. No. 11/430,437, Tamarkin et al., May 9, 2008, 27 pages. |
Office Action received from the U.S. Patent Office, U.S. Appl. No. 11/430,599, Jul. 28, 2008 (59 pages). |
Pendergrass, “The shape and dimension of the human vagina as seen in three-dimensional vinyl polysiloxane casts,” Gynecol Obstet. Invest. 1996:42(3):178-82. |
Prescription Information for Aldara, Mar. 2007 (29 pages). |
Prevent. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/prevent. 1 page. |
Psoriasis, http://www.quickcare.org/skin/causes-of0psoriasis.html. Accessed Sep. 9, 2010—3 pages. |
Purcell, Hal C. “Natural Jojoba Oil Versus Dryness and Free Radicals.” Cosmetics and Toiletries Manufacture Worldwide. 1988. 4 pages. |
Raschke, et al., “Topical Activity of Ascorbic Acid: From In Vitro Optimization to In Vivo Efficacy”, Skin Pharmacology and Physiology, 17(4):200-206 (2004)—Abstract, 1 page. |
Receptacle. Merriam Webster. Http://www.merriam-webster.com/dictionary/receptacle. Accessed Jul. 12, 2011. 1 page. |
Richwald, “Imiquimod”, Drugs Today, 35(7):497 (1999)—Abstract, 1 page. |
Rieger and Rhein. “Emulsifier Selection/HLB.” Surfactants in Cosmetics. 1997 (no month given). 1 page. |
Savin, et al., “Tinea versicolor treated with terbinafine 1% solution,” Int J. Dermatol, Nov. 1999; 38(11), pp. 863-865. |
Schulze, M.D., Harry “Iodine and Sodium Hypochlorite as Wound Disinfectants,” The British Medical Journal, pp. 921-922, 1915. |
Scientific Discussion for the approval of Aldara, EMEA 2005 (10 pages). |
Scott as Published in Pharmaceutical Dosage Forms; Disperse Systems, vol. 3, Copyright 1998, 120 pages. |
Seborrheic Dermatitis, http://www.cumc.columbia.edu/student/health/pdf/R-S/Seborrhea%20Dermatitis.pdf. Access Sep. 9, 2010, 2 pages. |
Shear, et al., “Pharmacoeconomic analysis of topical treatments for tinea infections,” Pharmacoeconomics. Mar. 1995; 7(3); pp. 251-267 (abstract only). |
Sheu, et al., “Effect of Tocopheryl Polyethylene Glycol Succinate on the Percutaneous Penetration of Minoxidil from Water/Ethanol/Polyethylene Glycol 400 Solutions”, Drug Dev. Ind. Pharm., 32(5):595-607 (2006)—Abstract, 1 page. |
Shim, et al., “Transdermal Delivery of Mixnoxidil with Block Copolymer Nanoparticles”, J. Control Release, 97(3):477-484 (2004)—Abstract, 1 page. |
Sigma Aldrich, “HLB-Numbers in Lithography Nanopatterning,” http://www.sigmaaldrich.com/materials-science/micro-and-nanoelectronics/1- ithography-nanopatterning/hlb-numbers.html, accessed: Feb. 2, 2009, pp. 1-3. |
Silicone. Definition. Retrieved Apr. 19, 2011 from http://www.oxforddictionaries.com/definition/silicone?view=uk. 1 page. |
Simovic, S. et al., “The influence of Processing Variables on Performance of O/W Emulsion Gels Based on Polymeric Emulsifier (Pemulen ÓTR-2NF),” International Journal of Cosmetic Science, vol. 2(2): abstract only. Dec. 24, 2001, 1 page. |
Skin Biology, CP Serum—Copper-Peptide Serum for Skin Regeneration and Reducing Wrinkles, Skin Biology, http;//web.archive.org/web/20030810230608/http://www.skinbio.com/cpserum.- html, Dec. 1, 2008, 21 pages. |
Skin Deep Cosmetics. PPG-40-PEG-60 Lanolin Oil http://www.cosmeticsdatabase.com/ingredient/722972/PPG-40-PEG-60—Lanolin—Oil/?ingred06=722972. 2010, 3 pages. |
Sonneville-Aubrun, O. et al. “Nanoemulsions: A New Vehicle for Skincare Products.” Advances in Colloid and Interface Science. 108-109.. 2004. pp. 145-149. |
Squire. J, “A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment ofdandruff/seborrhoeic dermatitis,” Dermatolog Treat. Jun. 2002;13(2):51-60 (abstract only). |
Sreenivasa, et al., “Preparation and Evaluation of Minoxidil Gels for Topical Application in Alopecia”, Indian Journal of Pharmaceutical Sciences, 68(4):432-436 (2006), 11 pages. |
Sugisaka, et al., “The Physiochemical Properties of Imiquimod, the First Imidazoquinoline Immune Response Modifier”, Abstract 3030, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
Tan et al., “Effect of Carbopol and Polyvinlpyrrolidone on the Mechanical Rheological and Release Properties of Bioadhesive Polyethylene Glycol Gels,” AAPS PharmSciTech, 2000; 1(3) Article 24, 2000, 10 pages. |
Tanhehco, “Potassium Channel Modulators as Anti-Inflammatory Agents”, Expert Opinion on Therapeutic Patents, 11(7):1137-1145 (2001)—Abstract, 3 pages. |
Tarumoto, et al., Studies on toxicity of hydrocortisone 17-butyrate 21-propionate—1. Accute toxicity of hydrocortisone 17-butyrate 21-propionate and its analogues in mice, rats and dogs (author's trans), J Toxicol Sci., Jul. 1981; 6 Suppl: 1-16 (Abstract only). |
Tata, et al., “Penetration of Minoxidil from Ethanol Propylene Glycol Solutions: Effect of Application Volume on Occlusion”, Journal of Pharmaceutical Sciences, 84(6):688-691 (1995). |
Torres-Rodriguez, JM., “New topical antifungal drugs,” Arch Med Res. 1993 Winter; 24(4), pp. 371-375 (abstract). |
Toxicology and Carcinogenesis Studies of t-Butyl Alcohol (CAS No. 75-65-0) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies), http://ntp.niehs.nih.gob/?objectid-=0709F73D-A849-80CA-5FB784E866B576D1. Accessed Dec. 9, 2008, 4 pages. |
Trofatter, “Imiquimod in clinical Practice”, European Journal of Dermatology, 8(7 Supp.):17-19 (1998)—Abstract, 1 page. |
Tsai, et al., “Drug and Vehicle Deposition from Topical Applications: Use of In Vitro Mass Balance Technique with Minosidil Solutions”, J. Pharm. Sci., 81(8):736-743 (1992)—Abstract, 1 page. |
Tsai, et al., “Influence of Application Time and Formulation Reapplication on the Delivery of Minoxidil through Hairless Mouse Skin as Measured in Franz Diffusion Cells”, Skin Pharmacol., 7:270-277 (1994). |
Tyring, “Immune-Response Modifiers: A New Paradigm in the Treatment of Human Papillomavirus”, Current Therapeutic Research, 61(9):584-596 (2000)—Abstract, 1 page. |
Uner, M. et al. “Skin Moisturizing Effect and Skin Penetration of Ascorbyl Palmitate Entrapped in Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) Incorporated into Hydrogel.” Pharmazie. 60. 2005. 5 pages. |
Veron, et al., “Stability of Minoxidil Topical Formulations”, Ciencia Pharmaceutica, 2(6):411-414 (1992), Abstract, 1 page. |
Williams, “Scale up of an olive/water cream containing 40% diethylene glycol momoethyl ether”, Dev. Ind. Pharm., 26(1):71-77 (2000). |
Wormser et al., Protective effect of povidone-iodine ointment against skin lesions induced by sulphur and nitrogen mustards and by non-mustard vesicants, Arch. Toxicol., 1997, 71, 165-170. |
Wormser, Early topical treatment with providone-iodine ointment reduces, and sometimes prevents, skin damage following heat stimulus, Letter to the Editor, Burns 24, pp. 383, 1998. |
Gill, A.M, et al., “Adverse Drug Reactions in a Paediatric Intensive Care Unit,” Acta Paediatr 84:438-441, 1995. |
Gladkikh, “Ascorbic Acid and Methods of Increasing its Stability in Drugs”, Translated from Khimiko-Farmatsevticheskii Zhurnal, 4(12):37-42 (1970)—1 page. |
Glaser, et al., Hyperhidrosis: A Comprehensive and Practical Approach to Patient Management, Expert Rev. Dermatol. 1(6), 773-775 (2006). |
Groveman, et al., “Lack of Efficacy of Polysorbate 60 in the Treatment of Male Pattern Baldness”, Arch Intern Med, 145:1454-1458 (1985). |
Gschnait, F., et al., “Topical Indomethacin Protects from UVB and UVA Irriadiation,” Arch. Dermatol. Res. 276:131-132, 1984. |
Hakan, et al., “The protective effect of fish oil enema in acetic acid and ethanol induced colitis,” The Turkish Journal of Gasroenterology, 2000, vol. 11, No. 2, pp. 155-161. |
Harrison, et al., “Posttherapy Suppression of Genital Herpes Simplex Virus (HSV) Recurrences and Enhancement of HSV-Specific T-Cell Memory by Imiquimod in Guinea Pigs”, Antimicrobial Agents and Chemotherapy, 38(9):2059-2064 (1994). |
Koerber, S., “Humectants and Water Activity,” Water Activity News, 2000, ISSN No. 1083-3943. |
Li, et al., “Solubility Behavior of Imiquimod in Alkanoic Acids”, Abstract 3029, Pharmaceutical Research, vol. 14, No. 11 Supplemental (November), p. S475 (1997), 2 pages. |
Merriam Webster Online Dictionary [online] retrieved from http://www.merriam-webster.com/cgi-bin/dictionary?book=dictionary&va=derivative on Jul. 5, 2008; 1 page. |
Merriam-Webster Online Dictionaary, 2008, “Mousse,” Merriam-Webster Online, Dec. 8, 2008 http://www.merriam-webster.com/dictionary/mousse, 2 pages. |
Olsen, et al., “A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men”, J. Am. Acad Dermatol, 57:767-774 (2007). |
OM Cinnamate. http://www.makingcosmetics.com/sunscreens/OM-Cinnamate-p102.html accessed Sep. 26, 2009, 1 page. |
Pakpayat, et al., “Formulation of Ascorbic Acid Microemulstions with Alkyl Polyglycosides”, European Journal of Pharmaceutics and Biopharmaceutics, 72:444-452 (2009). |
Paula. http://ww.cosmeticscop.com/cosmetic-ingredient-dictionary/definition/259/c12-15-alkyl-benzoate.aspx. Printed Oct. 24, 2010. 1 page. |
Raymond, Iodine as an Aerial Disinfectant, Journal of Hygiene, vol. 44, No. 5 (May 1946), pp. 359-361. |
Rosacea, http://clinuvel.com/skin-conditions/common-skin-conditions/rosacea#h0-6-prevention. Accessed Sep. 9, 2010, 5 pages. |
Schmidt A., “Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders,” Curtis., Jan. 1997; 59(1), pp. 21-24 (abstract). |
Sigma-Aldrich, Material Safety Data Sheet, Hydroxyethyl Cellulose, Mar. 3, 2004, 5 pages. |
Stehle et al., Uptake of minoxidil from a new foam formulation devoid of propylene glycol to hamster ear hair follicles, J. Invest. Dermatol., 2005, 124(4), A101. |
Sweetman, Sean C. Martindale: The Complete Drug Reference. 33rd Edition. London. Pharmaceutical Press. Jun. 21, 2002. pp. 1073 and 1473. 5 pages. |
Tadros, Tharwat F. “Surfactants in Nano-Emulsions.” Applied Surfactants: Principles and Applications. Wiley-VCH Verlag GmbH & Co. Weinheim. ISBN: 3-527-30629-3. 2005. pp. 285-308. |
Tata, et al., “Relative Influence of Ethanol and Propylene Glycol Cosolvents on Deposition of Minoxidil into the Skin”, Journal of Pharmaceutical Sciences, 83(10):1508-1510 (1994). |
Tsai, et al., “Effect of Minoxidil Concentration on the Deposition of Drug and Vehicle into the Skin”, International Journal of Pharmaceutics, 96(1-3):111-117 (1993)—Abstract, 1 page. |
Wermuth, C.G. “Similarity in drugs: reflections on analogue design,” Drug Discovery Today, vol. 11, Nos. 7/8, Apr. 2006, pp. 348-354. |
Karasu, T.B. et al., “Treatment of Patients with Major Depressive Disorder, Second Edition,” pp. 1-78, 2000. |
“Burn patients need vitamin D supplements.” Decision News Media, Jan. 23, 2004, http://www.nutraingredients.com/Research/Burn-patients-need-vitamin-D-supplements, Accessed: May 5, 2010. |
“Minocycline” accessed on Oct. 21, 2011 at en.wikipedia.org/wiki/Minocycline, 7 pages. |
“Reaction Rate” Accessed at en.wikipedia.org/wiki/Reaction—rate on Dec. 18, 2011, 6 pages. |
‘Niram Chemicals’ [online] Niram Chemicals, [retrieved on Jul. 17, 2012]. Retrieved from the Internet: <URL: http://www.indiamart.com/niramchemicals/chemicals.html>, 7 pages. |
Barry and Badal, “Stability of minocycline, doxycycline, and tetracycline stored in agar plates and microdilution trays,” Current Microbiology, 1978, 1:33-36. |
Cheshire, et al., Disorders of Sweating, www.medscape.com, Semin Neurol 23(4):399-406, 2003. |
Disorder. (2007). In the American Heritage Dictionary of the English Language. Retrieved from http://www.credoreference.com/entry/hmdictenglang/disorder. 1 page. |
Hargreaves, “Chemical Formulation, An Overview of Surfactant-Based Preparations Used in Everyday Life”, The Royal Society of Chemistry, pp. 114-115 (2003). |
Hormones. Http://www.greenwillowtree.com/Page.bok?file=libido.html. Jan. 2001. |
Hydroxyethylcellulose. Http: //terpconnect.umd.edu/-choi/MSDS/Sigma-Aldrich/HYDROXYETHYL%20CELLULOSE, 5 pages, Jan. 14, 2004. |
Jan. “Troubled Times: Detergent Foam.” http://zetatalk.com/health/theal17c.htm. Accessed Feb. 9, 2012. 2 pages. |
Joseph, “Understanding foams & foaming,” University of Minnesota (1997), at http://www.aem.umn.edu/people/faculty/joseph/archive/docs/understandingfoams.pdf, pp. 1-8. |
Lebwohl et al., “A randomized, double-blind, placebo-controlled study of clobestasol propionate 0.05% foam in the treatment of nonscalp psoriasis,” International Journal of Dermatology, 2002, 41(5):269-274. |
Martindale. 33 ed. London, Bath Press, 2002. pp. 1073 and 1473. |
Merck index, 10th edition, Merck & Co., Inc.: Rahway, NJ, 1983, pp. 39 (entry 242 for allantoin). |
Merck index, 14th edition, O'Neill, ed., 2006, entry for p-amino benzoic acid. |
Merck index, 14th edition, O'Neill, ed., 2006, entry for zinc oxide. |
Metronidazole. www.usp.org/pdf/EN/veterinary/metronidazole.pdf. accessed Sep. 10, 2009, 4 pages. |
Neutrogena. Http://www.cosmetoscope.com/2010/04/neutrogea-clinical-with-johnson-johnsons-cytomimic-techology/. Published Apr. 28, 2010. Accessed Sep. 11, 2010, 5 pages. |
Oil. Dictionary of Chemistry. Editor: DWA Sharp. Copyright 1990. |
Smith, Anne. “Sore Nipples.” Breastfeeding Mom's Sore Nipples: Breastfeeding Basics. http://breastfeedingbasics.com/articles/sore-nipples. Accessed Feb. 8, 2012. 9 pages. |
Surfactant. Chemistry Glossary. Http://chemistry.about.com/od/chemistryglossary/g/surfactant.htm, 2012, 1 page. |
Third Party Submission for U.S. Appl. No. 12/014,088, Feb. 4, 2009, 4 pages. |
Tzen, Jason T.C. et al. “Surface Structure and Properties of Plant Seed Oil Bodies.” Department of Botany and Plant Sciences, University of California, Riverside, California 92521. Apr. 15, 1992. 9 pages. |
Yamada and Chung, “Crystal Chemistry of the Olivine-Type Li(MnγFe1-γ)PO4 and (MnγFe1-γ)PO4 as Possible 4 V Cathode Materials for Lithium Batteries,” J. Electrochemical Soc., 2001, 148(8): A960-967. |
Material Safety Data Sheet, Progesterone, Apr. 26, 2006, 5 pages. |
Nietz, “Molecular orientation at surfaces of solids,” J. Phys. Chem., 1928, 32(2): 255-269. |
Padhi et al., “Phospho-olicines as positive-electrode materials for rechargeable lithium batteries,” J. Electrochemical Soc., 1997, 144(4): 1188-1194. |
Ravet et al., “Electroactivity of natural and synthetic triphylite,” J. of Power Sources, 2001, 97-98: 503-507. |
Shrestha et al., Forming properties of monoglycerol fatty acid esters in nonpolar oil systems, Langmuir, 2006, 22: 8337-8345. |
“Coal tars and coal-tar pitches,” Report on Carcinogens, Twelfth Edition, 2011, 3 pages. |
Adisen et al. “Topical tetracycline in the treatment of acne vulgaris,” J Drugs Dermatol., 2008, 7:953-5. |
Baskaran et al., “Poloxamer-188 improves capillary blood flow and tissue viability in a cutaneous burn wound,” J. Surg. Res., 2001, 101(1):56-61. |
Bell-Syer et al. “A systematic review of oral treatments for fungal infections of the skin of the feet,” J. Dermatolog. Treat., 2001, 12:69-74. |
Boehm et al. 1994, “Synthesis of high specific activity [.sup.3 H]-9-cis-retinoic acid and its application for identifying retinoids with unusual binding properties,” J. Med. Chem., 37:408-414. |
Carapeti et al., “Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects,” Dis Colon Rectum, 2000, 43(10):1359-62. |
Cook and Mortensen, “Nifedipine for treatment of anal fissures,” Dis Colon Rectum, 2000, 43(3):430-1. |
Dumortier et al., “A review of poloxamer 407 pharmaceutical and pharmacological characteristics,” Pharmaceutical Res., 2006, 23(12):2709-2728. |
Ebadi et al., “Healing effect of topical nifedipine on skin wounds of diabetic rats,” DARU, 2003, 11(1):19-22. |
Effendy and Maibach. “Surfactants and Experimental Irritant Contact Dermatitis.” Contact Dermatol., 1995, 33:217-225. |
Elias and Ghadially, “The aged epidermal permeability barrier,” Clinical Geriatric Medicine, Feb. 2002, pp. 103-120. |
Fantin et al., “Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (Quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus,” Antimicrob Agents and Chemothery, 1999, 39:400-405. |
Fluter et al., “Glycerol accelerates recovery of barrier function in vivo,” Acta Derm. Venereol,. 1999, 79:418-21. |
Garti et al. “Sucrose Esters microemulsions,” J. Molec. Liquids, 1999, 80:253-296. |
Hammer et al. “Anti-Microbial Activity of Essential Oils and other Plant extracts,” J. Applied. Microbiology, 1999, 86:985-990. |
Hwang et al. “Isolation and identification of mosquito repellents in Artemisia vulgaris,” J. Chem. Ecol., 11: 1297-1306, 1985. |
Knight et al., “Topical diltiazem ointment in the treatment of chronic anal fissure,” Br. J. Surg., 2001, 88(4):553-6. |
Kucharekova et al., “Effect of a lipid-rich emollient containing ceramide 3 in experimentally induced skin barrier dysfunction,” Contact Dermatitis, Jun. 2002, pp. 331-338. |
Leive et al, “Tetracyclines of various hydrophobicities as a probe for permeability of Escherichia coli outer membrane,” Antimicrobial Agents and Chemotherapy, 1984, 25:539-544. |
Luepke and Kemper, “The HET-CAM Test: An Alternative to the Draize Eye Test,” FD Chem. Toxic., 1986, 24:495-196. |
Osborne and Henke, “Skin Penetration Enhancers Cited in the Technical Literature,” Pharm. Technology, Nov. 1997, pp. 58-86. |
Padi. “Minocycline prevents the development of neuropathic pain, but not acute pain: possible anti-inflammatory and antioxidant mechanisms,” Eur J. Pharmacol, 2008, 601:79-87. |
Palamaras and Kyriakis, “Calcium antagonists in dermatology: a review of the evidence and research-based studies,” Derm. Online Journal, 2005, 11(2):8. |
Passi et al., Lipophilic antioxidants in human sebum and aging, Free Radical Research, 2002, pp. 471-477. |
Perrotti et al., “Topical Nifedipine With Lidocaine Ointment vs. Active Control for Treatment of Chronic Anal Fissure,” Dis Colon Rectum, 2002, 45(11):1468-1475. |
Repa et al. “All-trans-retinol is a ligand for the retinoic acid receptors,” Proc. Natl. Acad Sci, USA, 90: 7293-7297, 1993. |
Ruledge, “Some corrections to the record on insect repellents and attractants,” J. Am. Mosquito Control Assoc, 1988, 4(4): 414-425. |
Sakai et al., “Characterization of the physical properties of the stratum corneum by a new tactile sensor,” Skin Research and Technology, Aug. 2000, pp. 128-134. |
Schaefer, “Silicone Surfactants,” Tenside, Surfactants, Deterg., 1990, 27(3): 154-158. |
Simoni et al., “Retinoic acid and analogs as potent inducers of differentiation and apoptosis. New promising chemopreventive and chemotherapeutic agents in oncology,” Pure Appl Chem., 2001, 73(9):1437-1444. |
Smith, “Hydroxy acids and skin again,” Soap Cosmetics Chemical Specialties, 1993, pp. 54-59. |
Solans et al. “Overview of basic aspects of microemulsions,” Industrial Applications of Microemulsions, Solans et al Eds, New York, 1997, 66:1-17. |
Squillante et al., “Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin,” European J. Pharm. Biopharm., 1998, 46(3):265-71. |
Todd et al. “Volatile Silicone Fluids for Cosmetics,” 91 Cosmetics and Toiletries, 1976, 27-32. |
Torma et al., “Biologic activities of retinoic acid and 3, 4-dehydroretinoic acid in human keratinoacytes are similar and correlate with receptor affinities and transactivation properties,” J. Invest. Dermatology, 1994, 102: 49-54. |
USP23/NF 18 The United States Pharmacopeia: The National Formulary, US Pharmacopoeia, 1995, p. 10-14. |
Van Slyke, “On the measurement of buffer values and on the relationship of buffer value to the dissociation constant of the buffer and the concentration and reaction of the buffer solution,” J. Biol. Chem., 1922, 52:525-570. |
Van Cutsem et al., “The antiinflammatory efects of ketoconazole,” J. Am. Acad. Dermatol.,1991, 25(2 pt 1):257-261. |
Wang and Chen, “Preparation and surface active properties of biodegradable dextrin derivative surfactants,” Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2006, 281(1-3): 190-193. |
Weindl et al., “Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects,” Skin Pharmacology and Physiology, 2004, 17: 207-213. |
Xynos et al., “Effect of nifedipine on rectoanal motility,” Dis Colon Rectum, 1996, 39(2):212-216. |
Yamada et al., “Candesartan, an angiotensin II receptor antagonist, suppresses pancreatic inflammation and fibrosis in rats,” J. Pharmacol. Exp. Ther., 2003, 307(1)17-23. |
Paragraph E.3.1 of regulation (EC) No. 2003 (See Directive 67/548/EEC OJ 196, 16.8, 1967, p. 1. |
Tzen et al., Lipids, proteins and structure of seed oil bodies from diverse species; Plant Physiol., 1993, 101:267-276. |
Brown et al. “Structural dependence of flavonoid interactions with Cu2+ inos: implications for their antioxidant properties,” Biochem. J., 1998, 330:1173-1178. |
Cloez-Tayarani. et al., “Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine2A receptors,” Int. Immunol., 2003, 15:233-40. |
“Mineral oil USP,” Chemical Abstracts Service Registry No. 8012-95-1, 2011, 7 pages. |
“Tea tree oil,” Chemical Abstract No. 68647-73-4, 2012, 2 pages. |
Lin et al., “Ferulic acid stabilizes a solution of vitamins c and e and doubles its protoprotection of skin,” J Invest Dermatol, 2005, 125:826-32. |
Number | Date | Country | |
---|---|---|---|
20120195836 A1 | Aug 2012 | US |
Number | Date | Country | |
---|---|---|---|
60466094 | Apr 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10835359 | Apr 2004 | US |
Child | 12499609 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12499609 | Jul 2009 | US |
Child | 13400337 | US |